

70803 U.S. PTO
05/30/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING APPLICATION
Under Rule 53(a), (b)(i) & (d)(i)
(No Filing Fee or Oath/Declaration)
(Do NOT use for Provisional or PCT Applications)
Use for Design or Utility Applications

PATENT
APPLICATION

U.S. PTO
616/866279
05/30/97

RULE 53(d) NO DECLARATION

Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

Atty. Dkt.

234805

M#

Client Ref

Date: May 30, 1997

Sir:

1. This is a Request for filing a new PATENT APPLICATION (☐ Design ☒ Utility) entitled:

2. (Complete Title): **USE OF FLP RECOMBINASE IN MICE**

without a filing fee or Oath/Declaration but for which is enclosed the following:

3. ☒ Abstract 1 page(s).

4. 67 Pages of Specification (only spec. and claims); 5. ☐ Specification in non-English language

6. 49 Numbered claim(s); and

7. ☒ Drawings: 3 sheet(s) per set: ☐ 1 set informal; 8. ☒ formal of size: ☒ A4 ☐ 11"

9. **DOMESTIC/INTERNATIONAL** priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date
(1)		(4)	
(2)		(5)	
(3)		(6)	

10. **FOREIGN** priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in

Application No.	Filing Date	Application No.	Filing Date
(1)		(4)	
(2)		(5)	
(3)		(6)	

11. (No.) Certified copy (copies): ☐ attached; ☐ previously filed (date)
in U.S. Application No. / filed on

12. ☐ Amend the specification by inserting before the first line --This is a ☐ Continuation-in-Part
☐ Divisional ☐ Continuation ☐ Substitute Application (MPEP 201.09) of:

12(a) ☐ National Appln. No. / filed --- (M#)

12(b) ☐ International Appln. No. **PCT/** filed which designated the U.S. --

13. ☐ See top first page re continuing application ("X" only if info is there)

13(a) extension to date: ☐ concurrently filed ☐ not needed ☐ previously filed

14. ☐ Prior application is assigned to

by Assignment recorded Reel Frame

15. ☒ Attached: Computer readable form (CRF) of the Sequence Listing

16. This application is made by the following named inventor(s) (Double check instructions for accuracy.):

(1) Inventor	Susan	M.	Dymecki
	First	Middle Initial	Family Name
Residence	Baltimore	Maryland	USA
	City	State/Foreign Country	Country of Citizenship
Post Office Address	2809 Boston Street, Apt. #217, Baltimore, Maryland		
(include Zip Code)	21224		

(2) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(3) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(4) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(5) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

17. NOTE: FOR ADDITIONAL INVENTORS, check box ☐
and attach sheet with same information regarding additional inventors .


**Cushman Darby & Cushman
Intellectual Property Group of
Pillsbury Madison & Sutro LLP**

1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005-3918
Tel: (202) 861-3000
Attny/ Sec: PNK/GRT/maf

By: Atty: **Paul N. Kokulis**

Reg. No. **16,773**

Sig:



Fax: (202) 822-0944

Tel: (202) 861-3503

NOTE: File in duplicate with 2 post card receipts (CDC-103) & attachments

APPLICATION UNDER UNITED STATES PATENT LAWS

Invention: USE OF FLP RECOMBINASE IN MICE

Inventor (s): Susan M. DYMECKI

Cushman Darby & Cushman
Intellectual Property Group of
Pillsbury Madison & Sutro, LLP
1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005-3918
Attorneys
Telephone: (202) 861-3000

This is a:

- ☐ Provisional Application
- ☒ Regular Utility Application
- ☐ Continuing Application
- ☐ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application

SPECIFICATION

USE OF FLP RECOMBINASE IN MICE

GOVERNMENT RIGHTS

The invention described herein was made in the course of work under grant number R55-HD30830-01 and R01-HD30830 from the National Institutes of Health. The U.S. Government may retain certain rights in this invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the use of Flp recombinase to catalyze *FRT* site-specific DNA recombination in a transgenic non-human mammal, preferably a mouse.

2. Description of the Related Art

Site-specific recombinases are being developed as tools for genetic engineering because of their simplicity and precise activity in a variety of organisms. Two well studied recombinases are Flp and Cre. For use *in vivo*, a recombinase should be active in a transgenic non-human mammal. While Cre-mediated recombination has been successfully employed in transgenic mice, the utility of Flp recombinase in transgenic mice has not previously been established.

U.S. Pat. No. 4,959,317 discloses the use of the Cre-*lox* recombinase system in yeast and cultured mammalian cells, but not in transgenic mice. Other site-specific recombinases were not discussed.

U.S. Pat. No. 5,527,695 demonstrates the use of Flp recombinase in plants, but not in cultured mammalian cells or transgenic mice. A number of different site-specific

6229333

recombinase systems are discussed; however, no guidance appears to be given for selecting among the different systems and their use in a transgenic mouse is not discussed.

Kilby et al. (1993) reviewed the demonstrated activities of different site-specific recombinases in cells and organisms. Table 1 shows that, to their knowledge, Flp recombinase activity in transgenic mice had not been accomplished.

Flp-mediated deletion was demonstrated in embryonic stem (ES) cells by Jung et al. (1993). Gu et al. (1993) compared the activity of Cre and Flp recombinases in ES cells and found "a major fraction of ES cells transiently transfected by the *cre* vector undergo Cre-*loxP*-mediated gene deletion (which is not the case in our hands if the related FLP/FRT system from yeast is used [Jung et al., 1993, and unpublished data])". Both papers were contributed by the Rajewsky group, and the same group has exclusively used the Cre-*loxP* system in transgenic mice to inactivate endogenous genes, instead of Flp recombinase (Gu et al., 1994; Kühn et al., 1995). Thus, prior to the present invention, it was thought that using Cre recombinase was preferred over using Flp recombinase.

In view of the above teachings of the related art, it is an unexpected finding of the present invention that Flp recombinase can function in a developing mammal to catalyze *FRT* site-specific recombination.

Moreover, although Cre recombinase has been successfully used to create specific deletions in the mouse genome, the general utility of Cre to catalyze recombination is currently being established. Therefore, an additional method is needed for generating site-specific genetic alterations in the following ways: (1) a site-specific recombinase demonstrating a different dose-sensitivity could be used in situations where proper regulation of the recombination event cannot be achieved using Cre and (2) two site-

specific recombinases could be used *in vivo* to engineer simultaneous or sequential recombination reactions (e.g., independent gene activation or inactivation events).

For example, site-specific recombinases may be used to activate expression of a tracer molecule to mark cell lineages. Factors that influence the determination of these cell lineages can be identified by analyzing these marked cells in the genetic background of various mutations, including mutations generated using the second recombinase system. Additionally, having access to two recombinase systems allows for efficient use of the first recombinase to generate a mutation, and the second recombinase to remove any selectable markers used in generating that mutation which, if left in place, would confound interpretation of the study. A second recombinase system is desired which exploits the ability of Flp recombinase to catalyze FRT-specific recombination in a transgenic non-human mammal which can be used alone or to expand the uses of the *Cre/loxP* system.

The present invention provides a transgenic non-human mammal with sufficient Flp recombinase activity to catalyze recombination between *FRT* sequences, a transgenic non-human mammal containing FRT target nucleic acid which serves as an efficient substrate for Flp, a process of *in vivo* gene manipulation using the transgenic non-human mammals, and a genetic system comprised of the Flp transgenic non-human mammal and the FRT target transgenic non-human mammal which contains at least one *FRT* sequence.

BRIEF SUMMARY OF THE INVENTION

An object of the invention is to provide a transgenic non-human mammal with Flp recombinase activity useful for manipulation of the genome in the intact mammal.

Yet another object of the invention is to provide a process of *in vivo* genetic engineering using Flp recombinase activity to catalyze *FRT* site-specific recombination in a non-human mammal.

A further object of the invention is to provide a genetic system of the transgenic non-human mammal with Flp recombinase activity and at least one nucleic acid which is a substrate for Flp recombinase (e.g., the nucleic acid contains a *FRT* sequence). The nucleic acid may also contain a transgene for insertion into the genome of a non-human mammal, or a region which directs homologous recombination into the genome of a non-human mammal.

In one embodiment of the invention, a transgenic non-human mammal is provided which contains a Flp transgene integrated in its genome. Optionally, at least one Flp-recognition sequence is also integrated in the genome of the transgenic non-human mammal. The Flp-recognition sequence comprises *FRT* or a derivative thereof such as, for example, SEQ ID NO:14 or SEQ ID NO:15. A transgenic non-human mammal of the invention contains sufficient Flp recombinase activity in a cell to catalyze recombination between Flp-recognition sequences of the cell, chromosomal and/or extrachromosomal. Flp recombinase activity may be regulated by a chemical (e.g., exogenously administered drug, endogenous metabolite), the mammal's developmental stage, its body temperature, or tissue type of the cell.

The substrate for Flp recombinase activity is a Flp-recognition sequence. The genome of the transgenic non-human mammal may comprise one Flp-recognition sequence, two Flp-recognition sequences, or more than two Flp-recognition sequences. A chimeric or mosaic transgenic non-human mammal may contain cells with different

numbers of Flp-recognition sequences due to Flp-mediated recombination; when a Flp-recognition sequence is integrated on only one of the pair of homologous chromosomes, the genome will be hemizygous for the Flp-recognition sequence.

Recombination between two Flp-recognition sequences integrated on different chromosomes results in translocation between those chromosomes. Such translocations are a common means of creating mutations that lead to developmental abnormalities or tumorigenesis.

Recombination between two Flp-recognition sequences in direct repeat orientation may cause excision of an intervening DNA sequence (e.g., a gene). Although such events are potentially reversible because Flp-mediated recombination is conservative, loss of the excised DNA sequence during cell division or by degradation makes the mutation irreversible. A null mutation in any gene may be created in this way, and the function of the gene studied in specific cells and/or at specific developmental stages.

Recombination between two Flp-recognition sequences in inverted repeat orientation may cause inversion of an intervening sequence or gene. As in *Salmonella* phase variation, inversion may cause activation or inactivation of a gene. If gene activity is detectable (e.g., selectable marker, histochemical marker, reporter gene), cell lineages may be traced by identifying recombination events that mark a cell and its descendants through detection of gene activation or inactivation. Cell lineages may be traced independent of gene activity, by monitoring differences in the integration site of the Flp substrate.

Recombination between a Flp-recognition sequence integrated on a chromosome and a Flp-recognition sequence integrated on extrachromosomal genetic material may

cause insertion of the genetic material into the chromosome. An insertion created in this manner would provide means for creating transgenic non-human mammals with site-specific integration of a single copy of the transgene at a site in the genome specified by the chromosomal FLP-recognition sequence. Transgene insertion at a defined site in the genome would ensure reproducibility of expression because confounding effects of variable chromatin structure would be minimized.

Preferably, the intervening sequence or genetic material contains a gene such as, for example, a developmental gene, essential gene, cytokine gene, neurotransmitter gene, neurotransmitter receptor gene, oncogene, tumor suppressor gene, selectable marker, or histochemical marker, or portion thereof. Recombination may cause activation or inactivation of a gene by juxtaposition of regulatory regions to the gene or separation of regulatory regions from the gene, respectively.

The transgenic non-human mammal of the invention may also contain a Cre recombinase transgene. A cell of the transgenic non-human mammal would contain sufficient Cre recombinase activity to catalyze recombination between Cre-recognition sequences (e.g., *lox* site) of the cell.

A second embodiment of the invention is a process for *in vivo* genetic engineering using the transgenic non-human mammal. FLP recombinase activity is induced in a cell containing at least two FLP-recognition sequences at a level sufficient to catalyze site-specific recombination in the cell. This results in recombination between FLP-recognition sequences in the cell. The cell may be of germ line or somatic origin. If recombination occurs in a germ cell or a totipotent cell, offspring may be produced with a genome altered by the recombination event. A process for studying carcinogenesis and its treatment is

provided by using Flp-mediated recombination to cause activation of an oncogene or inactivation of a tumor suppressor gene. Candidate compounds or compositions may be screened in such a process to identify candidates that act to promote carcinogenesis (i.e., a cancer promoter) or inhibit carcinogenesis (i.e., a cancer inhibitor). Similarly, Flp-mediated recombination in a transgenic non-human mammal may be used in a process of activating ectopic expression of a gene during development, inactivating expression of a gene at a specific time or in a specific tissue, or identifying a cell lineage by activation or inactivation of a gene. The gene may be a developmental gene, essential gene, cytokine gene, neurotransmitter gene, neurotransmitter receptor gene, oncogene, tumor suppressor gene, selectable marker, or histochemical marker.

In a third embodiment of the invention, a genetic system comprising the transgenic non-human mammal and a purified nucleic acid containing at least one Flp-recognition sequence is provided. Preferred nucleic acids include the vectors described herein. Optionally, the genetic system may also comprise means for producing a transgenic non-human mammal which contains at least some portion of the purified nucleic acid; preferably, at least the Flp-recognition sequence is integrated into the genome of the transgenic non-human mammal.

As used herein, a transgenic non-human mammal is a non-human mammal into which genetic material has been introduced with a recombinant nucleic acid. The introduced genetic material may become integrated into the genome of the non-human mammal, preferably stably- or excisably-integrated into a chromosome of the non-human mammal, and be transmitted through the germ line to a succeeding generation.

Alternatively, the genetic material may be maintained as an episome or an artificial chromosome.

Any such introduced genetic material is termed a transgene. If the transgene is unstable or is excised during cell division, the result will be a mosaic mammal comprised of at least two cell types with different genetic content but derived from the same zygote. Such an mammal may be used in cell lineage tracing; thus, a transgene flanked by *FRT* sites may be excised during ontogeny by the action of Flp recombinase. In contrast, a chimeric mammal comprises at least two genetically different cell types derived from different zygotes (e.g., a mammal resulting from injection of embryonal carcinoma or embryonic stem cells into a genetically different blastocyst). If the transgenic non-human mammal only contains the transgene in somatic cells, the transgene will not be passed to a succeeding generation through the germ line.

Preferably, the non-human mammal is a mammal for which methods to introduce a transgene are known in the art such as, for example, cow, goat, mouse, pig, rabbit, rat and sheep. Such methods of introducing genetic material include microinjection for the creation of transgenics from zygotes; and electroporation, biolistics, lipofection, calcium phosphate-DNA co-precipitation, DEAE-dextran, microinjection, and viral infection for the creation of transgenics from a cultured cell (e.g., pluripotent cells such as a teratocarcinoma or embryonal carcinoma, totipotent cells such as an embryonic stem cell) and subsequent transfer into an embryo.

The transgenic non-human mammal, the process, and the genetic system are particularly advantageous when separate control of more than one recombination event is desired in the mammalian genome. For example, integration of a *loxP* sequence-

containing substrate may be followed by deletion of a selectable marker from the substrate which is mediated by Flp recombinase activity catalyzing recombination between *FRT* sequences flanking the selectable marker, and Cre-mediated recombination of the *loxP*-containing substrate. Integration of the *loxP* sequence containing substrate is preferably by homologous recombination, and expression of the co-integrated selectable marker enriches for this rare event; the second event occurs by Flp-mediated site-specific recombination which deletes the selectable marker to reduce competition from the regulatory regions of the selectable marker; and the third event of deleting gene sequences lying between *loxP* sites occurs by Cre-mediated site-specific recombination.

DESCRIPTION OF THE DRAWINGS

Figure 1. Structure of the modular fusion vectors. Each functional segment is represented by a patterned rectangle (not drawn to scale); the name of each segment is boxed and described below. Enzymes in parentheses cut twice in the vectors (except plasmid pFRT₂ which contains three *Xba*I sites), all other enzymes shown are unique. A unique *Cla*I site at the junction of *trpS* and *lacZ* sequences is not diagrammed because it is resistant to cleavage when grown on Dam⁺ *E. coli* strains. All vectors, except pFRT₂, are built on a pUC19-derived plasmid backbone containing Ap^R (Yanisch-Perron et al., 1985; Fire et al., 1990). Plasmid pFRT₂ is built on a pCR backbone containing both Ap^R and Km^R (Invitrogen). Complete sequences for all vectors are available from GenBank (accession numbers U46489-U46493). (Fig. 1A) Structure of the *Flp*-expression vector. To generate pFlp, sequences were removed from p16.43 (Fire et al., 1990) and replaced with a *Xba*I-*Sa*I fragment containing the synthetic intron, *Flp*, and SV40 p(A) from

pOG44 (O’Gorman et al., 1991). (Fig. 1B) Structure of the *lacZ* fusion vector *placZ*. (Fig. 1C) Structure of the target *FRT* vectors. The *FRT*-cassette was constructed in two steps. Double-stranded oligos (oligo pairs SD1/SD3 and SD2/SD4) were ligated and then amplified by PCR using oligo pair SD9/SD10. The 150-bp PCR product bracketed by *AgeI* sites was then inserted into pCR (Invitrogen) to generate pFRT₂. Oligos used to construct the *FRT*₂-*AgeI* cassette include SD1 (SEQ ID NO:1), SD2 (SEQ ID NO:2), SD3 (SEQ ID NO:3), SD4 (SEQ ID NO:4), SD9 (SEQ ID NO:5), and SD10 (SEQ ID NO:6).

Plasmid pFRT₂*lacZ* was generated by inserting the *FRT*₂-*AgeI* fragment from pFRT₂ into the unique *AgeI* site in *placZ*. This insertion disrupts the *NLS::trpS::lacZ* open reading frame; there are no ATG codons downstream of the *AgeI* site to start translation of functional βGal. Plasmid pFRT₂neo*lacZ* contains the Nm^R gene (*XhoI*-*BamHI* fragment) from pNeoβGal (O’Gorman et al., 1991) inserted between the *BglIII* and *XhoI* sites of pFRT₂*lacZ*. The orientation of *neo*^R is opposite to *lacZ*. Plasmid pFRT*lacZ* was generated by digesting pFRT₂*lacZ* with *XbaI* and religating. Corresponding *FRT* vectors have been generated which contain a SV40 small *t* intron immediately 5’ to the p(A) (*XbaI*-*NotI* fragment from pEμSv; Rosenbaum et al., 1989). These vectors are designated the “t” series (*placZ.t*, pFRT₂*lacZ.t*, pFRT₂neo*lacZ.t* and pFRT*lacZ.t*). “FRT₂” defines two target sites in the same orientation; “FRT” refers to a single target site. Abbreviations used for restriction enzymes are as follows: *AgeI* (A); *Apal* (Ap); *AvrIIc* (Av); *BamHI* (B); *BglIII* (Bg); *BssHIII* (Bs); *BstBI* (Bt); *BstXI* (Bx); *EagI* (E); *EcoRI* (RI); *EcoRV* (RV); *HindIII* (H); *KpnI* (K); *NheI* (Nh); *NotI* (N); *PstI* (P); *SacI* (Sa); *SalI* (S); *SmaI* (Sm); *SnaBI* (Sn); *SpeI* (Sp); *SphI* (Sh); *Sse8387I* (Ss); *StuI* (St); *Tth111I* (T); *XbaI* (X); *Xcal* (Xc); *XhoI* (Xh).

Figure 2. Schematic and partial sequence of the β Gal fusion protein predicted to be encoded by the product of Flp-mediated recombination (the nucleotide sequence shown is SEQ ID NO:7 and the protein sequence shown is SEQ ID NO:8). Linked in order are the initiating ATG codon, the 8-aa SV40 T antigen nuclear localization signal (NLS, SEQ ID NO:9), the 16-aa domain encoded by the residual *FRT* (SEQ ID NO:10), the 27-aa TrpS linker (SEQ ID NO:11), and β Gal. The *FRT* consists of two 13-bp inverted repeats (SEQ ID NOS:12-13) flanking an 8-bp spacer that comprise the minimal Flp-recognition sequence (SEQ ID NO:14), plus an additional 13-bp repeat (SEQ ID NO:15).

Figure 3. DNA constructs and the Flp-mediated recombination event. Structure of target and recombinase transgenes. Flp recombination targets (*FRT*s) are depicted as black triangles. Rectangles represent exons; heavy lines, introns and flanking regulatory sequences; thin lines, vector sequences; and small arrows, translation start sites. Hybridization probes are represented by numbered lines. PCR oligonucleotide primers are represented by small half arrows. (Fig. 3A) Structure of target transgenes. Plasmid pFRTZ (for *FRT*-disrupted *lacZ* transgene) contains 3.9-kb of sequence from the human β -actin (*hACTB*) gene (Gunning et al., 1987; Zhang et al., 1994) inserted into the target vector pFRT₂neo.lacZ; a nuclear localization signal (NLS) and SV40 early polyadenylation (pA) sequence are also included. pFRTZ.2 is an alternative target plasmid which contains the *HSV-tk* gene inserted between the *FRT* sequences of pFRTZ. Control plasmid pFRTZ-product represents the product of Flp-mediated excisional recombination. Restriction sites and probe 1 used in Southern analyses are shown on pFRTZ. (Fig. 3B) Structure of *FLP* transgenes. Plasmid pACTB::FLP contains the 3.9-kb *hACTB* fragment inserted into the expression vector pFLP, which contains a synthetic

intron, Flp-encoding sequence, and SV40 late pA sequence from pOG44 (O’Gorman et al., 1991; Stratagene). pRevhACTB::FLP contains the hACTB sequences in reverse orientation and serves as a negative control. Plasmid pWnt1::FLP contains the synthetic intron, Flp-encoding sequence and the SV40 late pA from pFLP inserted into the polylinker of the *Wnt-1* expression vector pWEXP2 (26). Probe 2 is used in the whole mount *in situ* hybridization analyses; probe 3 is used in the Northern analyses. (Fig. 3C)

Diagram of the FLP-mediated excisional recombination reaction.

DETAILED DESCRIPTION OF THE INVENTION

Site-specific recombinases of the integrase family, including Flp, are being developed as tools for genetic engineering because of their simplicity and precise activity in a broad range of organisms (Broach et al., 1982; Cox, 1983; Vetter et al., 1983; Stark et al., 1992; Kilby et al., 1993; Snaith et al., 1995). Flp recombinase from the yeast *Saccharomyces cerevisiae* can catalyze excision, insertion, inversion, and translocations of DNA containing Flp-recognition target sites without other cofactors (Cox, 1983; Vetter et al., 1983). The type of recombination product is determined by the orientation of target sites relative to each other on a segment of DNA (Stark et al., 1992; Kilby et al., 1993): directly repeated sites specify excision of intervening DNA, inverted sites specify inversion of intervening DNA, and sites on separate DNA molecules specify either translocation, insertion, or duplication (a special case of insertion with identical DNA molecules). Controlled recombinase expression in an organism bearing chromosomal recombinase target sites can be used to generate tissue-specific mutations, or to assess the effect of ectopic gene expression in a subset of cells with an otherwise normal organism.

These applications are particularly desirable when studying the effect of lethal or otherwise deleterious mutations, or when null mutations of a gene do not result in an observable phenotype. Such controlled gene expression and manipulation can also be used to activate or inactivate a lineage tracer in populations of cells and their descendants, so that cell lineages can be identified and functionally characterized. Together, these applications provide a means to address many previously intractable problems in mammalian development.

Flp recombinase recognizes a distinct 34-bp minimal site which tolerates only limited degeneracy of its recognition sequence (Jayaram, 1985; Senecoff et al., 1988). In site-specific recombination, the substrate DNA is broken at two points and the ends are exchanged, with no synthesis or degradation of DNA (i.e., conservative recombination). For example, recombination with a circular DNA substrate can have three outcomes: a single circle resolved into two circles, two circles fused into one, or a segment within a circle can be inverted with respect to the rest of the circular molecule. To achieve a precise joint in the recombined product, the recombinase must locate the sites for cutting and rejoining the substrate, bring them together, and catalyze digestion, exchange and ligation of the substrate in a well-regulated manner. The top and bottom strand cuts are at fixed points within the crossover region but staggered, such that cleavage on both strands would give recessed 3' ends.

Controlled recombinase expression in a transgenic non-human mammal carrying appropriately placed target sites in its genome can be exploited to alter the genotype of a subset of cells within an otherwise normal embryo or adult. Such mosaic mammals bearing clones of genetically distinct somatic cells have been most extensively generated

in *Drosophila*, providing new means to address previously intractable problems. For example, Flp-mediated excisional recombination may be used to irreversibly activate or inactivate a marker gene in specific cell populations and their descendants, allowing cell lineages to be studied; similarly, genes of interest may be ectopically expressed to study their effects on differentiation and development. By promoting mitotic exchange between target sites on homologous chromosomes, Flp provides an effective methodology for F_1 genetic screens. By catalyzing recombination between target sites on the same DNA molecule or between targets sites on different DNA molecules, the Flp site-specific recombinase can be used to study a variety of biological processes. Importantly, such recombination schemes can be used to generate tissue- or stage-specific mutations that would be lethal if generated in the whole organism. Controlled Flp recombinase expression, in an organism carrying chromosomal Flp recombinase target (*FRT*) sites, can be used to generate tissue- or stage-specific mutations, or to assess the effects of transgene expression in a subset of cells within an otherwise normal mammal.

In the examples below, the nucleotide sequence of the Flp gene used was SEQ ID NO:16 and the Flp protein had amino acid sequence SEQ ID NO:17. The wild-type Flp gene from *Saccharomyces cerevisiae* has nucleotide sequence SEQ ID NO:18 which encodes the amino acid sequence SEQ ID NO:19.

The wild-type Flp recombinase is most active at 23-30°C and loses activity at higher temperatures. The Flp recombinase used in the examples below include the F70L mutation which has the characteristics of a temperature-sensitive mutation with activity between 23-30°C equivalent to that of wild-type Flp recombinase, but little activity at 37°C and above (Buchholz et al., 1996). This led to the recommendation by Stewart's

group that Cre recombinase be used rather than Flp recombinase in applications that require “quantitative recombination”. In contrast, the present invention illustrates the utility of non-human mammals containing Flp transgenes.

By use of the degenerate genetic code, variant nucleotide sequences may be generated that are translated into SEQ ID NO:16 and, thus, encode Flp protein. Variant nucleotide sequences may be selected for translation by considering the frequency of codon usage in the non-human mammal. Functional equivalents of the disclosed nucleotide sequence may be generated by making minor sequence variations in SEQ ID NO:15 and measuring recombinase activity of the translated variant protein. A functional equivalent of Flp recombinase would mediate site-specific recombination more efficiently than random recombination, and produce recombined *FRT* sequence joints by precise cleavage and ligation. The degree of sequence variation may be assessed by low or high stringency hybridization with a target sequence of SEQ ID NO:15, or by reference to substitution of codons for chemically similar amino acid residues. Examples of Flp variants are given in Kulpa et al., (1993). Variant proteins may also be selected with desired properties such as thermolability, thermostability, altered cellular localization, altered sequence recognition, and/or modified frequency of recombination. For example, a Flp variant comprising a nuclear localization signal and Flp recombinase as a fusion protein may be used to target Flp recombinase to the nucleus, and thereby increase the frequency of recombination.

Flp recombinase activity may have its expression controlled by a regulatory region operably linked to a Flp transgene. By appropriate choice of regulatory region, Flp recombinase activity may be regulated by a chemical (e.g., drug administered to the

mammal, endogenous metabolite of the mammal), developmental stage, temperature, type of tissue or cell of origin, or a combination thereof. The regulatory region may express the transgene in a broad (e.g., ubiquitously) or narrow (e.g., tissue specific) range of tissues, at varying levels of expression which may lead to different frequencies of recombination, or in a sustained or transient manner. Similar regulatory regions may be operably linked to a developmental gene, essential gene, cytokine gene, neurotransmitter, neurotransmitter receptor, oncogene, tumor suppressor gene, selectable marker, or histochemical marker to confer desired expression on the gene or marker; such gene or marker may be genetically manipulated *in vivo* by linkage to a Flp-recognition sequence and the action of Flp-mediated recombination.

Regulatory regions may control transcription (e.g., promoter, enhancer, silencer, rate of elongation), post-transcriptional events (e.g., editing, splicing, message stability, polyadenylation, transport out of the nucleus), translation (e.g., initiation, elongation, termination), or post-translational events (e.g., secretion and transport, cell localization, folding, assembly, protease cleavage or degradation, acylation, glycosylation, sulfation, phosphorylation, isomerization). Transcription may be regulated by, for example, tetracycline, bacteriophage RNA polymerase, IPTG, heavy metal, steroid, viral infection, expression of a DNA-binding factor, modulation of a DNA-binding factor by chemical inducers of dimerization, developmental stage, heat, tissue type, or a combination thereof. Regulatory regions may be selected from genes such as, for example, metallothionein, heat shock protein, globin, immunoglobulin heavy chain, lens crystallin, muscle creatine kinase, elastase, enolase, serum-responsive genes, major histocompatibility complex class II, interferon-responsive genes, steroid-responsive genes or the like. Regulatory regions

for ubiquitous expression may be selected from genes such as, for example, β -actin, phosphoglycerate kinase, HMG-CoA reductase, major histocompatibility complex class I, β 2-microglobulin, HSV thymidine kinase gene, Rous Sarcoma Virus regulatory elements, CMV immediate-early gene, SV40 origin, or the like.

Examples of regulatory regions and useful methods of gene expression are given in Goeddel (1990), Kriegler (1990), and Murray (1991). U.S. Pat. No. 5,221,778 describes a binary transgenic system comprised of a line with a transactivator-dependent promoter controlling expression of a transgene crossed to a line expressing the transactivator ubiquitously, at specific times, or in specific cells. Such a system may be used to regulate the Flp recombinase transgene in the parent or in offspring.

Examples of developmental genes that may be studied by Flp-mediated recombination include: adhesion molecules (e.g., N-CAM, cadherins, integrins), cyclin kinase inhibitors (e.g., p27, p21, p16, p15), Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines, interleukins, growth/differentiation factors (e.g., BMPs, EGF, netrin, PDGF, TGF- β) and their receptors, neurotransmitters and their receptors, kinase and phosphatases, metabolic enzymes such as tyrosine hydroxylase, antigen receptors (TCR and Ig). The gene may be expressed in a temporal and spatial pattern that mimics endogenous gene regulation to rescue lethal mutations, or otherwise complement mutant genes. While expressing the developmental gene in cells responsible for the lethal phenotype, the function of the gene may be determined in other cell types by selectively inactivating gene expression in those other cells. The function of a gene may also be determined by over expressing the gene. A developmental gene may also be expressed ectopically, that is expressed in a temporal

or spatial pattern that does not mimic the endogenous patterns of expression. Thus, the function of the gene may be determined at a stage of the cell or in a type of cell with a different developmental program than is normally encountered through inactivation, over expression, or ectopic expression.

A series of recombination events may be controlled by the use of multiple Flp-recognition sites, or by the use of different site-specific recombination systems. Control of a series of recombination events may be accomplished by a competition for Flp recombinase by a multitude of identical Flp-recognition sites; recombination between identical Flp-recognition sites will then occur stochastically because the Flp-recognition sites may be used as substrates of Flp recombinase at equivalent frequencies. The physical contacts between Flp recombinase and a *FRT* sequence have been examined (Panigrahi et al., 1992). Alternatively, derivatives of the *FRT* sequence may be used as Flp-recognition sites: if the derivative is used as a substrate of Flp recombinase with lower efficiency, then Flp-mediated recombination at that site will occur less frequently; or if the derivative is used as a substrate of Flp recombinase with higher efficiency, then Flp-mediated recombination at that site will occur more frequently. Recombination between two Flp-recognition sequences results in a hybrid Flp-recognition sequence (i.e., a 13-bp repeat from a first Flp-recognition sequence and a 13-bp repeat from a second Flp-recognition sequence); thus, two barely functional *FRT* derivatives, each with a mutation in a 13-bp repeat (termed a half site), will exchange half sites after Flp-mediated recombination and may result in one functional *FRT* and one non-functional *FRT*. Examples of variant *FRT* sequences are given by Jayaram (1985) and Senecoff et al. (1988), and an assay for Flp-mediated recombination on different substrates is described

by Snaith et al. (1996). Besides sequence diversity, the efficiency of Flp recombinase for a given substrate may be determined by local copy number of Flp-recognition sequences, or chromatin structure.

Recombination frequency may also be controlled by using derivatives of Flp recombinase which may have altered functions such as binding of the recognition sequence, cleavage of DNA, and rejoining of DNA. Fusion proteins comprising a Flp recombinase domain may be engineered to make recombinase activity of the fusion protein dependent on the availability of a diffusible ligand and binding of the ligand to the fusion protein (Logie and Stewart, 1995). A Flp transgene may be expressed under the control of a regulatory region that confers stage- or tissue-specific expression as described hereinabove. Flp recombinase may be expressed as part of a binary system, i.e. the Flp transgene may be operably linked to a regulatory region which is responsive to a transcription factor and the transcription factor is produced by another transgene which is integrated at a site not linked to the integration site of the Flp transgene. Preferably, the Flp transgene is regulated by a substance that is not naturally found in the transgenic host such as, for example, tetracycline (U.S. Pat. No. 5,589,362), cyclophilin (Belshaw et al., 1996), ecdysone (No et al., 1996), IPTG (U.S. Pat. Nos. 4,833,080 and 5,589,392), T7 RNA polymerase (U.S. Pat. No. 5,550,035). An alternative to controlling recombinase activity is to separate the recognition and catalytic domains of the Flp recombinase into separate polypeptides that are non-functional on their own, but that are brought together to form a functional recombinase when a diffusible binding molecule is administered to the transgenic mouse, to multimerize Flp recombinase monomers, to translocate Flp recombinase into the nucleus, or to recruit transcriptional activators that control expression

of the Flp recombinase transgene (e.g., chemical inducer of dimerization; Belshaw et al., 1996; Crabtree and Schreiber, 1996); or to engineer a fusion protein of Flp and a ligand-binding domain (Logie and Stewart, 1995).

Moreover, a distinct site-specific recombination system may be used (e.g., Cre-*lox*) to differentially control a series of recombination events by expressing Flp and Cre recombinases independently of each other.

A genetic system with a first line of non-human mammal with a Flp transgene and a second line of transgenic non-human mammal with a transgene containing at least one Flp-recognition site is another way of regulating Flp-mediated recombination. By breeding the two transgenic lines, the Flp transgene and its substrate will be present and Flp-mediated recombination will occur in cells with sufficient Flp recombinase activity and access to substrate.

In a mosaic or a chimeric transgenic non-human mammal, cells that have undergone site-specific recombination between Flp-recognition sequences may contain different numbers of Flp-recognition sequences. In mosaic or chimeric transgenic non-human mammals that have undergone Flp-mediated inversion of a second transgene flanked by Flp-recognition sequences in inverted repeat orientation, cell lineages may be traced by activation (e.g., transcription of the sense strand by a juxtaposed regulatory region) or inactivation (e.g., deletion or separation from a regulatory region) of the second transgene. The second transgene is preferably a histochemical marker for tracing cell lineages, but *in situ* hybridization of transcripts from the second transgene is a possible method of detecting gene expression. Histochemical markers or reporter genes include alkaline phosphatase, β -galactosidase, chloramphenicol acetyltransferase, luciferase, green

fluorescent protein, β -glucuronidase, or derivatives thereof (Wasserman and DePamphilis, 1993). For *in situ* hybridization, radioactive labels may be used, but non-radioactive methods using an enzymatic label as described above and avidin-biotin or digoxigenin-antibody interaction. Another way of assaying gene activity would be to tag the marker gene with a peptide sequence (i.e., a fusion protein) that is capable of specific binding, and to detect the presence of the fusion protein with a cognate binder of the peptide tag. Useful peptide tag-binder pairs include, but are not limited to, avidin-biotin, GST-glutathione, polyHis-divalent metal, MBP-maltose, 9E10 Myc epitope-antibody, protein A/G-immunoglobulin, and SV40 T antigen-antibody.

Fiering et al. (1995) have described a method for gene replacement by homologous recombination, followed by site-specific recombination in ES cells to delete a selectable marker. First, the gene is replaced by homologous recombination in ES cells with positive (*neo*) - negative (HSV *tk*) selection. Homologous recombination results in retention of the *neo* selectable marker and loss of the HSV *tk* selectable marker at the homologously recombined locus, but removal of the remaining selectable marker is essential to eliminate competition between endogenous promoters and the promoter of the selectable marker. The *neo* expression cassette was deleted by Flp-mediated recombination in ES cells, but Fiering et al. did not express Flp recombinase in a transgenic mouse. Examples of selectable markers include neomycin phosphotransferase, hygromycin phosphotransferase, puromycin N-acetyl transferase, dihydrofolate reductase, HSV thymidine kinase, adenosine deaminase, hypoxanthine-guanine phosphoribosyl transferase, and adenine phosphoribosyl transferase. Cells carrying the marker may be selected through use of an exogenously added drug or an endogenous metabolite.

The process of screening candidate drugs that affect tumorigenesis will be directed to particular oncogenes or tumor suppressor genes. By controlling Flp-mediated recombination, such genes can be activated, inactivated, or otherwise mutated in a tissue- or temporal-specific manner. For example, MYC recombination may be directed to lymphocytes by expressing Flp recombinase with a lymphocyte-specific regulatory region from immunoglobulin heavy chain (IGH). A preferred means of activating MYC would be translocation to the IGH locus as occurs in murine plasmacytoma or human Burkitt lymphoma. A tumor suppressor gene such as RB1 could be inactivated by deletion or point mutation by expressing Flp recombinase with a crystallin regulatory region. In the foregoing, by controlling activation (MYC) or inactivation (RB1) in the cellular compartment (lymphocyte or lens, respectively) in which the gene functions, the model recapitulates a natural process of tumorigenesis.

Control of different recombination events would be useful in investigating models of multi-hit carcinogenesis, or in determining whether an immortalized or transformed phenotype can be reversed by inactivation of an oncogene (Westerman and Leboulch, 1996) or activation of a tumor suppressor gene.

A non-limiting list of oncogenes includes ABL1, BCL1, BCL2, BCL6, CBFA2, CBL, CSF1R, ERBA, ERBB, EBRB2, ETS1, ETV6, FGR, FOS, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TAL1, TCL3, and YES. The Flp recombinase system may be used to mutate the oncogene or its homologs by genetic means such as, for example, excision, integration (which may lead to duplication of the gene), inversion, translocation, or a combination thereof; types of mutation include amplification, deletion, gain of function,

insertion, loss of expression, loss of function, over expression, or a combination thereof. Some oncogenes, especially those that encode transcription factors, are mutated by chromosome translocation or inversion; regulatory regions may be juxtaposed to the coding region of the oncogene to cause aberrant expression, or a fusion protein may be formed from all or part of the oncogene (reviewed by Rabbitts, 1994; Sorensen and Triche, 1996). Other oncogenes are often activated by point mutations that have functional consequences (e.g., gain of function, loss of function) upon translation of the oncoprotein. Oncogenes may be over expressed by gene amplification, or activation by regulatory regions that are juxtaposed by recombination next to the oncogene. Tumors may be of hematologic origin (e.g., leukemia, lymphoma) or a solid tumor.

Tumor suppressor genes include, but are not limited to, APC, BRCA1, BRCA2, MADH4, MCC, NF1, NF2, RB1, WT1, and TP53. Defined deletions of the tumor suppressor gene or its homologs may be made in whole, or in part, by Flp-mediated recombination. Flp recombinase may mutate the tumor suppressor gene or its homologs by the means previously described for oncogenes, or may induce a loss of heterozygosity by inactivating a functional tumor suppressor gene or its homologs which is allelic to a recessive mutation. The gene sequence may encode the tumor suppressor gene or its homologs, or may contain a region that regulates expression of the tumor suppressor or its homologs at the level of, for example, transcription or translation. Flp recombinase activity may induce a chromosome translocation which disrupts the coding sequence of the tumor suppressor gene or its homologs, or separates the coding sequence from essential regulatory regions. Small intragenic or large chromosome inversions may serve the same purpose.

The above-mentioned names follow the genetic nomenclature of Online Mendelian Inheritance in Man (May 1997), Center for Medical Genetics, Johns Hopkins University and National Center for Biotechnology Information, National Library of Medicine. Either the human gene or its homolog may be introduced into the non-human mammal as a transgene, or an endogenous homolog of the human gene may be genetically manipulated in the non-human mammal. Such manipulation may include introduction of one or more FRT sequences within or nearby the homologous gene by means known in the art.

All books, articles and patents cited in this specification are incorporated herein by reference in their entirety.

REFERENCES

1. Belshaw, P.J., Ho, S.N., Crabtree, G.R., and Schreiber, S.L. (1996) Proc. Natl. Acad. Sci. USA 93:4604-4607.
2. Bonneret, C., Rocancourt, D., Briand, P., Grimber, G. and Nicholas, J.-F. (1987) Proc. Natl. Acad. Sci. USA 84:6795-6799.
3. Brinster, R.L., Allan, J.M., Behringer, R.R., Gelinas, R.E. and Palmiter, R.D. (1988) Proc. Natl. Acad. Sci. USA 85:836-840.
4. Broach, J.R., Guarascio, V.R. and Jayaram, M. (1982) Cell 29:227-234.
5. Buchholz, F., Ringrose, L., Angrand, P.O., Rossi, F. and Stewart, A.F. (1996) Nucleic Acids Res. 24:4256-4262.
6. Buchman, A.R. and Berg, P. (1988) Mol. Cell. Biol. 8:4395-4405.
7. Burrell, H. (1995) Epicentre Forum 2:4-5.
8. Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162:156-159.
9. Cox, M.M. (1983) Proc. Natl. Acad. Sci. USA 80:4223-4227.

10. Crabtree, G.R. and Schreiber, S.L. (1996) *Trends Biochem. Sci.* 21:418-422.
11. Echelard, Y., Epstein, D.J., St.-Jacques, B., Shen, L., Mohler, J., McMahon, J.A. and McMahon, A.P. (1993) *Cell* 75:1417-1430.
12. Echelard, Y., Vassileva, G. and McMahon, A.P. (1994) *Development* 120:2213-2224.
13. Feinberg, A. and Vogelstein, B. (1993) *Anal. Biochem.* 132:6-13.
14. Fire, A., Harrison, S.W. and Dixon, D. (1990) *Gene* 93:189-198.
15. Goeddel, D.V. (1990). *Gene Expression Technology*. Meth. Enzymol. vol. 185.
16. Gorman, C.M., Merlino, G.T., Willingham, M.C., Pastan, I. and Howard, B.H. (1982) *Proc. Natl. Acad. Sci. USA* 79:6777-6781.
17. Gu, H., Zou, Y.-R. and Rajewsky, K. (1993) *Cell* 73:1155-1164.
18. Gu, H., Marth, J.D., Orban, P.C., H. Mossmann and Rajewsky, K. (1994) *Science* 265:103-106.
19. Gunning, P., Leavitt, J., Muscat, G., Ng, S. and Kedes, L. (1987) *Proc. Natl. Acad. Sci. USA* 84:4831-4835.
20. Hall, C., Jacob, P., Ringold, G. and Lee, F. (1983) *J. Mol. Appl. Genet.* 2:101-109.
21. Hogan, B., Constantini, F. and Lacy, E. (1986) *Manipulating the Mouse Embryo*. CSHL Press, Plainview, NY, pp. 152-203.
22. Huang, M.T.F. and Gorman, C.M. (1990) *Nucleic Acids Res.* 18:937-947.
23. Jayaram, M. (1985) *Proc. Natl. Acad. Sci. USA* 82:5875-5879.
24. Jung, S., Rajewsky, K. and Radbruch, A. (1993) *Science* 259:984-987.
25. Kalderon, D., Richardson, W.D., Markham, A.F. and Smith, A.E. (1984a) *Cell* 39:499-509.

26. Kalderon, D., Richardson, W.D., Markham, A.F. and Smith, A.E. (1984b) *Nature* 311:33-38.
27. Kilby, N.J., Snaith, M.R. and Murray, J.A.H. (1993) *Trends Genet.* 9:413-421.
28. Kozak, M. (1987) *Nucleic Acids Res.* 15:8125-8148.
29. Kriegler, M. (1990) *Gene Transfer and Expression*. Stockton Press, New York, NY.
30. Kühn, R., Schwenk, F., Aguet, M. and Rajewsky, K. (1995) *Science* 269:1427-1429.
31. Kulpa, J., Dixon, J.E., Pan, G. and Sadowski, P.D. (1993) *J. Biol. Chem.* 268:1101-1108.
32. Logie, C. and Stewart, A.F. (1995) *Proc. Natl. Acad. Sci. USA* 92:5940-5944.
33. Murray, E.J. (1991) *Gene Transfer and Expression Protocols*. Humana Press, Clifton, NJ.
34. No, D., Yao, T.P., and Evans, R.M. (1996) *Proc. Natl. Acad. Sci. USA* 93:3346-3351.
35. O'Gorman, S., Fox, D.T. and Wahl, G.M. (1991) *Science* 251:1351-1355.
36. Panigrahi, G.B., Beatty, L.G. and Sadowski, P.D. (1992) *Nucleic Acids Res.* 20:5927-5935.
37. Rabbitts, T.H. (1994) *Nature* 372:143-149.
38. Robertson, E., Bradley, A., Kuehn, M. and Evans, M. (1986) *Nature* 323:445-448.
39. Robertson, E.J. (1987) In: Robertson, E.J. (Ed.), *Teratocarcinomas and Embryonic Stem Cells*. IRL Press, Oxford, pp. 71-112.
40. Rosenbaum, H., Webb, E., Adams, J.M., Cory, S. and Harris, A.W. (1989) *EMBO J.* 8:749-755.
41. Rudnicki, M.A. and McBurney, M.W. (1987) In: Robertson, E.J. (Ed.) *Teratocarcinomas and Embryonic Stem Cells*. IRL Press, Oxford, pp. 19-49.

42. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning*. CSHL Press, Plainview, NY, pp. 7.43-7.52.
43. Sanes, J.R., Rubenstein, J.L.R. and Nicolas, J.F. (1986) EMBO J. 5:3133-3142.
44. Schuurin, E., Deemter, L.V., Roelink, H. and Nusse, R. (1989) Mol. Cell. Biol. 9:1357-1361.
45. Senecoff, J.F., Rossmeissl, P.J. and Cox, M.M. (1988) J. Mol. Biol. 201:405-421.
46. Snaith, M.R., Murray, J.A.H. and Boulter, C.A. (1995) Gene 166:173-174.
47. Snaith, M.R., Kilby, N.J. and Murray, J.A. (1996) Gene 180:225-227.
48. Sorensen, P.H. and Triche, T.J. (1996) Semin. Cancer Biol. 7:3-14.
49. Stark, W.M., Boocock, M.R. and Sherratt, D.J. (1992) Trends Genet. 8:432-439.
50. Stuhl, G. and Basler, K. (1993) Cell 72:527-540.
51. Thomas, K.R. and Capecchi, M.R. (1987) Cell 51:503-512.
52. Vetter, D., Andrews, B.J., Roberts-Beatty, L. and Sadowski, P.D. (1983) Proc. Natl. Acad. Sci. USA 80:7284-7288.
53. Wasserman, P.M. and DePamphilis, M. (1993) *Guide to Techniques for Mouse Development*. Meth. Enzymol. vol. 225.
54. Westerman, K.A. and Leboulch, P. (1996) Proc. Natl. Acad. Sci. USA 93:8971-8976.
55. Wilkinson, D.G., Bailes, J.A. and McMahon, A.P. (1987) Cell 50:79-88.
56. Wilkinson, D.G. (1992) In: Wilkinson, D.G. (Ed.), *In Situ Hybridization*. IRL Press, Oxford, pp. 75-83.
57. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) Gene 33:103-119.

58. Zhang, M., Kim, H., Marshall, H., Gendron-Maguire, M., Lucas, D.A., Baron, A., Gudas, L.J., Gridley, T., Krumlauf, R. and Grippo, J.F. (1994) Development 120:2431-2442.

The following examples are meant to be illustrative of the present invention; however, the practice of the invention is not limited or restricted in any way by them.

EXAMPLE 1

Flp Recombinase and Target *FRT* Vectors

A set of versatile Flp recombinase and target vectors was constructed to facilitate using the Flp recombinase to manipulate DNA in cell culture and in the whole animal. These vectors are described below and shown in Fig. 1.

pFlp (SEQ ID NO:15), a vector for directed expression of Flp recombinase: The pFlp plasmid contains unique 5' and 3' polylinker segments (multiple cloning sites, MCS), to facilitate insertion of regulatory elements to direct recombinase expression (Fig. 1A). This plasmid consists of a 5' MCS, Flp coding sequence (O'Gorman et al., 1991), SV40 late orientation p(A) sequence and a 3' MCS. A synthetic intron (Huang and Gorman, 1990; O'Gorman et al., 1991) has been placed upstream of the Flp coding region to maximize expression.

placZ, a lacZ fusion vector for use in vertebrate cells: Rapid and precise histochemical staining procedures make β Gal a good reporter for assays of gene expression in transgenic animals. To facilitate construction of *lacZ* fusions for expression in vertebrate cells, the plasmid placZ has been generated. It is comprised of a 5' MCS, a

KpnI-cassette containing a start Met codon and a nuclear localization signal (NLS), the β Gal-coding region, SV40 early p(A) sequence and a 3' MCS (Fig.1B).

The *KpnI*-cassette in *placZ* contains an ATG within an optimized vertebrate translation start sequence (Kozak, 1987), followed by sequences in frame that encode the NLS of SV40 T antigen (Kalderon et al., 1984a). For transcriptional fusions where translation starts at this ATG, the NLS will reside on the N-terminus of β Gal and can confer tight nuclear localization upon β Gal (Kalderon et al., 1984b; Bonneret et al., 1987). Nuclear-localized β Gal, in contrast to cytoplasmic β Gal, can help identify marked cells in the context of complex tissues and can readily be distinguished from any endogenous cytoplasmic β Gal activity. Nuclear localization of β Gal also permits simultaneous immunodetection of cytoplasmic cell identity markers allowing for unambiguous phenotyping of β Gal marked cells. If the translation start signal and NLS are not desired, the cassette can be removed by cutting with *KpnI* (or *Asp718I*).

The β Gal-coding region was derived from an *E. coli trpS::lacZ* fusion (Hall et al., 1983; Fire et al., 1990). Consequently, the *lacZ*-containing vectors encode fusion proteins with a short peptide leader from TrpS attached to the N-terminus of β Gal.

Target FRT vectors: Recombinase target vectors have been generated that allow specific combinations of *FRT*s, signals for RNA processing and protein targeting, selection markers, and reporter genes (or other DNA sequences) to be linked as needed (Fig. 1C).

The '*FRT*₂-*AgeI* cassette' vector (pFRT₂) contains two recombination target sites in direct orientation flanked by *AgeI* sites. Each target site consists of two 13-bp inverted repeats flanking an 8-bp spacer (the minimal F1p-recognition site), plus an additional 13-

bp repeat that can enhance substrate activity (Jayaram, 1985). The nucleotide sequence of a single *FRT* target site is shown in Fig. 2. In plasmid pFRT₂ a MCS has been engineered between the *FRT* sites to allow insertion of various DNA sequences.

The *FRT*-disrupted (silent) *lacZ* fusion vector, pFRT₂*lacZ*, was designed to optimize expression of *lacZ* and detection of βGal following Flp-mediated excisional recombination. It was generated by inserting the FRT₂-*AgeI* fragment from pFRT₂ into the unique *AgeI* site in *placZ*. This *AgeI*-insertion disrupts the *NLS::trpS::lacZ* open reading frame. Because there are no ATG codons to start translation of functional βGal downstream of the *AgeI* site, βGal activity is strictly dependent on Flp-mediated excisional recombination. Following Flp-recombination, pFRT₂*lacZ* encodes a fusion protein containing an 8-aa NLS, a 16-aa domain encoded by the residual *FRT*, and a 26-aa peptide leader from TrpS attached to the N-terminus of βGal (Fig. 2). This βGal fusion protein generates robust enzyme activity in mammalian cells.

Plasmid pFRT₂neo.*lacZ* contains the Nm^R gene, *MCI::neo^R::pA* (O’Gorman et al., 1991), inserted between the *FRT*s of pFRT₂*lacZ*. The *neo^R* gene enables selection of transgene integrants in cell culture. Plasmid pFRT.*lacZ* represents the expected product of Flp recombination and serves as a useful ‘pre-activated’ control.

To enhance transcript processing, stability and translation in mammalian cells (Brinster et al., 1988; Buchman and Berg, 1988; Huang and Gorman, 1990), a set of plasmids has been constructed that contain the SV40 small *t* intron immediately 5’ to the p(A). The modified vectors comprise the “t” series (pFRT₂*lacZ*.t, pFRT₂neo.*lacZ*.t, pFRT.*lacZ*.t and *placZ*.t).

Considerations When Building Transcriptional Fusions

Transcriptional fusions use regulatory regions from the gene of interest linked so that translation starts at the ATG within the *KpnI*-NLS-cassette. When designing such fusions it is important that the initiating ATG of NLS be the first ATG codon in the mRNA. The ATG in the *SphI* site in the 5' MCS therefore precludes use of the *HindIII* and *SphI* sites as right-hand junctions in transcriptional fusions (Fire et al., 1990). If chosen regulatory regions contain introns, the transcriptional fusion should not be constructed in the "t" vectors. The presence of the SV40 small *t* intron 3' to *lacZ* may result in aberrant splicing if additional introns are fused 5'.

Flp-Dependent β Gal Activity in Mammalian Cell Culture

The integrity of the Flp, *FRT* and *lacZ* vectors has been confirmed by restriction mapping, nucleotide sequencing and demonstration of Flp-dependent β Gal activity following cotransfection of embryonic fibroblasts. For the cotransfection assays, regulatory sequences from the human β -actin-encoding gene (*hACTB*) were used to direct transgene expression (Gunning et al., 1987; Zhang et al., 1994). A 3.9-kb sequence from *hACTB* (3-kb 5' flank, 78-bp 5' untranslated region, and 832-bp first intron) was inserted into the 5' MCS sites of pFlp, pFRT₂neo.lacZ, pFRT.lacZ and placZ to generate phACTB::Flp, phACTB::FRT₂neo.lacZ, phACTB::FRT.lacZ and phACTB::lacZ, respectively.

In transient transfection experiments using primary embryonic fibroblasts (Robertson, 1987), robust nuclear β Gal activity was observed by XGal histochemical staining (Sanes et al., 1986) two days following calcium phosphate transfection (Gorman

et al., 1982) with the “pre-activated” constructs phACTB::FRT.lacZ and phACTB::lacZ. In contrast, β Gal activity from the phACTB::FRT₂neo.lacZ construct was observed only following cotransfection with phACTB::Flp. Plasmid phACTB::FRT₂neo.lacZ transfected alone, or with *Flp* driven by the hACTB promoter in the reverse orientation, showed no detectable β Gal activity.

Conclusions

(1) Flp recombinase and *FRT* target vectors have been generated. When fused to hACTB regulatory sequences, these vectors have been shown to function in mammalian cells with β Gal activity strictly dependent on co-expression of Flp. The SV40 NLS fused to the *FRT*-encoded domain (the residual *FRT* following recombination) can confer nuclear localization on β Gal in mammalian cells. Having validated these vectors in cell culture, they are used below to establish a histochemical marking system in the mouse to study cell lineage.

(2) Because *lacZ* can be activated by Flp-mediated excisional recombination, these vectors would be expected to enable activation or excision of any transgene of interest.

(3) The unique restriction sites in pFlp facilitate insertion of a variety of regulatory elements to direct Flp expression, and therefore recombination, to specific cells or tissues of a transgenic non-human mammal.

(4) By coupling tissue-specific Flp expression with insertion of *FRTs* in the mouse genome by homologous gene replacement techniques it would be possible to delete or mutate gene segments in restricted cell populations in the transgenic non-human mammal.

In this way, the effect of different mutations can be analyzed in specific cell populations in the background of an otherwise normal animal.

(5) The modularity of these vectors allows them to be readily modified for additional applications such as targeting insertions in the genome or generating chromosomal rearrangements (e.g., insertion, inversion, deletion, duplication, and translocation).

EXAMPLE 2

Materials and Methods

Plasmid Constructions and Production of Transgenic Mice

The *FRT*-disrupted *lacZ* target vector (pFRTZ; Fig. 3A) was generated by inserting the *Hind*III-*Sal*I fragment from pSLh β APr-*lacZ*-pA (Zhang et al., 1994) containing human β -*actin* (*hACTB*) sequences (3-kb 5' flank, 78-bp 5' untranslated region (*UTR*), and 832-bp first intron; Gunning et al., 1987) into the unique *Hind*III and *Sal*I sites of pFRT₂neo.*lacZ*. The control plasmid pFRTZ-product was constructed by inserting the same *hACTB Hind*III-*Sal*I fragment into pFRT.*lacZ*. A variant of pFRTZ (designated pFRTZ.2) was generated by inserting the 1.9-kb *Xho*I-*Sal*I fragment from pIC19R-MC1TK (Thomas and Capecchi, 1987) containing the *HSV-thymidine kinase* (*HSV-tk*) gene between the *FRT* sequences of pFRTZ. Plasmid pNeo β Gal (O'Gorman et al., 1991; Snaith et al., 1996; Stratagene) was also used as target DNA. The *FLP* transgene expression vector, phACTB::*FLP* (Fig. 3B), was constructed by inserting the 3.9-kb *Xba*I-*Sal*I fragment from pSLh β APr-*lacZ*-pA into the unique *Xba*I site of pFLP. A non-expressing, negative control *FLP* vector (pRevhACTB::*FLP*) was constructed which

contains identical *hACTB* sequences in reverse orientation. To generate pWnt1::FLP, the 2-kb *SaII* fragment from pFLP, containing a synthetic intron, the sequence encoding Flp (O’Gorman et al., 1991; Stratagene), and SV40 early polyadenylation (pA) sequence, was inserted into the unique *EcoRV* site of pWEXP2 (Echelard et al., 1993). To produce transgenic mice, transgenes were purified away from plasmid sequences and injected into fertilized eggs from B6SJL_{F1} X B6SJL_{F1} mice as described by Hogan et al. (1986).

Cell Culture

CCE ES cells (Robertson et al., 1986) were plated onto mitomycin C-treated STO fibroblasts (Robertson, 1987) in Dulbeccos’s modified Eagle medium (DMEM) supplemented with 15% fetal bovine serum (FBS), 2 mM glutamine, 0.1 mM β -mercaptoethanol, 2000 units/ml of leukemia inhibitory factor (LIF; ESGRO, Gibco BRL), 0.1 mM MEM-non essential amino acids, and 30 μ M nucleosides. Primary embryonic fibroblasts (EF) were prepared from hemizygous transgenic embryos 13.5 days post coitum (dpc) as described by Robertson (1987). P19 embryonal carcinoma (EC) cells were maintained in a 1:1 mixture of DMEM and Ham F2 medium supplemented with 7.5% FBS and 2 mM glutamine.

Transient Transfection

Transient transfection of ES cells (2×10^5 CCE ES cells in 3.5 cm dishes) was by lipofection (Lipofectamine, Gibco BRL) using 0.5, 2 or 4 μ g of plasmid phACTB::FLP (or negative control vector pRevhACTB::FLP), and 0.5 μ g of either pFRTZ or pFRTZ-product. β -Galactosidase (β Gal) activity was detected *in situ* using 4-Cl-5-Br-3-indolyl- β -d-galactosidase (XGal) (Sanes et al., 1986). Primary EF cultures were plated (5×10^4

cells/ml) in 3.5 cm dishes and transfected by calcium phosphate precipitation (Gorman et al., 1982) with 3 µg of the target pFRTZ or target pNeoβGal (O'Gorman et al., 1991) followed by XGal stain 48 hours later. P19 EC cells were plated (5×10^4 cells/ml) in 10 cm dishes. The next day, pairs of duplicate dishes were transfected by calcium phosphate precipitation (Gorman et al., 1982) with 5 µg of target pFRTZ.2 alone, 5 µg of pFRTZ.2 + 5 µg of phACTB::FLP, or 5 µg of pFRTZ.2 + 5 µg of pWnt1::FLP. Twenty-four hours later, half the dishes were treated with either 0.5 µM all-*trans* retinoic acid (RA, Sigma) or control diluent for an additional five days after which cells were stained with XGal.

Detection of Transcripts

Whole mount *in situ* hybridization to 9.5 dpc embryos was performed as described by Wilkinson (1992) using single-strand digoxigenin-UTP labeled RNA probes. The FLP probe (antisense probe 2, Fig. 3B) was a 1386-bp *EcoRV*-*Apal* fragment from the 3' end of the FLP transgene; control probe (sense) was a 648-bp *XbaI*-*EcoRV* fragment. For Northern analyses, fresh tissue or EF cells were homogenized in 6 M guanidinium isothiocyanate and RNA isolated using acid:phenol (Chomczynski et al., 1987). Total cellular RNA (20 µg) was separated and assayed for hybridization to FLP sequence as described by Sambrook et al. (1989). Ethidium bromide staining of the gel and filter was used to confirm equivalent RNA loading.

Molecular Analysis of Transgenic Mouse Genotypes

Mouse tails were lysed with NaDodSO₄/proteinase K and treated with phenol/chloroform, 1:1 (vol/vol), precipitated with ethanol, and dissolved in 10 mM Tris·HCL, pH 8 and 1 mM EDTA. For PCR analysis, DNAs were amplified with the following primers: SD42 (SEQ ID NO:20) and SD41 (SEQ ID NO:21), for the *FLP*

transgene (0.75-kb amplified fragment); SD49 (SEQ ID NO:22) and SD68 (SEQ ID NO:23), for the *FRTZ* transgene (1.4-kb amplified fragment) and *FRTZ-product* (0.25-kb fragment). The 0.25-kb PCR amplification product was cloned into plasmid pCR (Invitrogen) and sequenced; sequence analysis of the 0.25-kb product showed precise site-specific recombination. Genomic DNA isolated from freshly harvested tissues (Burrell, 1995) was subjected to *Bam*HI/*Sca*I digestion, and Southern blot analyses. Radiolabeled DNA fragments (specific activity of $2\text{-}5 \times 10^8$ cpm/ μ g) for use as probes were prepared by random priming (Feinberg and Vogelstein, 1993). Transgene copy number was estimated by including standard amounts of the injected transgene in parallel. Quantitation of radioactivity in specific bands was performed with a Molecular Dynamics PhosphorImager.

Strategy Used to Assay Flp Function in Cell Culture and the Mouse

To generate a test recombination substrate for Flp function, a *lacZ* gene was disrupted by inserting an *FRT* cassette that contains stop codons in all three reading frames. This target transgene is referred to as *FRTZ*, for *FRT*-disrupted *lacZ* (Fig. 3A). Because the two *FRT* sequences flanking the cassette are in the same orientation, Flp activity should excise the intervening DNA leaving a single residual *FRT* in frame with *lacZ* (Fig. 3C). Because there are no ATG codons to initiate translation of functional β Gal downstream of the *FRT*-cassette, β Gal activity is strictly dependent on Flp-mediated excisional recombination in a manner similar to previously described gain-of-function systems (O'Gorman et al., 1991; Struhl and Basler, 1993).

To broadly express both *FLP* and the *FRT*-disrupted *lacZ* target (*FRTZ*), both transgenes were placed under the control of regulatory sequences from the human β -actin (*hACTB*) gene (Fig. 3A, B). These *hACTB* sequences have been shown to be active in most tissues in transgenic mice (Zhang et al., 1994). A “recombined” control transgene, *FRTZ-product*, representing the predicted product of Flp recombination was also constructed (Fig. 3A).

Flp-Mediates Efficient Recombination of Extrachromosomal DNA in ES Cells

The efficacy of Flp-mediated excisional recombination of extrachromosomal DNA in ES cells was tested by assaying for gain of β Gal activity following transient cotransfection with target and recombinase plasmids. Cells were transiently transfected with either pFRTZ plus phACTB::FLP, or pFRTZ plus the negative control plasmid pRevhACTB::FLP, followed by XGal stain 48 hours later. Positive control cultures were transfected with the “recombined” plasmid, pFRTZ-product. Cultures transfected with target plasmid pFRTZ, alone or with pRevhACTB::FLP, showed no detectable β Gal activity; in contrast, robust activity was observed following cotransfection with phACTB::FLP.

To estimate recombinase activity, XGal-positive cells in each transfection were counted and compared. The number of cells staining blue after transfection with the control “recombined” pFRTZ-product reflected transfection efficiency and, since constitutively active, the maximal number of β Gal-positive cells. Cotransfection with a fixed amount of target plasmid and increasing amounts of *FLP* expression vector resulted in an increasing percentage of XGal-positive cells relative to control pFRTZ-product

transfections. A comparison between experimental (pFRTZ + phACTB::FLP) and control (pFRTZ-product) transfections showed that Flp-mediated β Gal activation occurred in at least 30% of transfected ES cells and could be as high as 78%. This increase in recombination with increasing Flp-encoding plasmid likely reflects more Flp protein produced per cell, as well as an increase in the proportion of cells that took up both the target and Flp-encoding plasmids (and thereby had the potential to activate *lacZ*).

Flp Can Be Generally Expressed in the Mouse Without Deleterious Effects

To determine whether Flp can function in the mouse and whether Flp expression, itself, would have any adverse effects, mice carrying the hACTB::FLP transgene were generated. To identify mouse lines producing Flp in a wide range of tissues, F1 mice from each founder (4917, 4924, 4925, 4927, 4921) were screened for ubiquitous *FLP* mRNA and recombinase activity. The distribution and amount of *FLP* mRNA was assessed in the embryo by whole mount *in situ* hybridization using antisense probe 2 (Fig. 3B) and a control sense probe, and in adult tissues by Northern analysis using hybridization to 32 P-labeled probe 3 (Fig. 3B). Two of the five hACTB::FLP mouse lines exhibited broad patterns of *FLP* transcripts in 9.5 dpc hemizygous embryos (mouse lines 4917 and 4924) and in adult tissues (e.g., testes, brain, heart, intestine, kidney, lung, ovary, striated muscle). Line 4924 expressed in the liver, but liver expression for line 4917 was weak; line 4917 expressed in the spleen and uterus, but there was only variable expression in those organs for line 4924.

Flp recombinase activity was assayed in embryonic fibroblast (EF) cultures derived from each transgenic mouse line. Primary EF cultures were prepared from hemizygous

hACTB::FLP transgenic embryos as described by Robertson (1987), transiently transfected with 3 µg of target pNEOβ-GAL plasmid (O’Gorman et al., 1991), and followed 48 hours later by histochemical Xgal staining (Sanes et al., 1986). As indicated by the number of blue cells, maximal Flp activity (approximately 45% of the “recombined” control) was observed in lines 4917 and 4924, the same mouse lines that showed broad *FLP* expression. The amount of recombinase activity detected in EF cultures also correlated with the amount of *FLP* mRNA isolated from each culture. From these results, it can be inferred that mouse lines 4917 and 4924 are the best candidates for broadly expressed active recombinase. Because no abnormalities were detected in founders or offspring, it is likely that Flp activity is nontoxic and can be used in most cell types.

Flp is Necessary and Sufficient to Recombine Target Sequences in Transgenic Mice

To test whether Flp activity can recombine a chromosomal target *in vivo*, mice carrying the *FRT*-disrupted *lacZ* transgene, *FRTZ*, were generated. Five transgenic founders were obtained. F₁ mice from four of the five founders bred as expected for unique single-site integration events (one founder failed to transmit the transgene). Southern analysis of liver DNA isolated from each mouse line showed that three of the four mouse lines carried the target *FRT*-disrupted *lacZ* transgene in head-to-tail array: line 4999 carried an array of approximately 4 copies of the *FRTZ* transgene, line 4998 had 11 copies, and line 5000 had 30 copies. Transgene transmission was mendelian and no rearrangements were observed.

The ability of Flp to catalyze *in vivo* recombination of the target *FRTZ* transgene was initially examined by crossing these mouse lines with the Flp producing lines

described above (4917 and 4924). Tail DNA from doubly transgenic animals was analyzed by PCR using primers (diagrammed in Fig. 3A,B) specific for detecting either the *FRTZ* transgene, the recombined target *FRTZ-product*, or the *FLP* transgene. Analyses of progeny from three distinct crosses are show the product of Flp-mediated excisional recombination at the *FRTZ* locus was amplified only in DNA isolated from doubly transgenic mice and was not detected in littermates transgenic for only the recombinase or the target gene. All three *FRTZ* target lines were found to be competent for recombination by this assay. Sequence analysis of the 0.25-kb amplification product showed precise site-specific recombination.

Flp Mediates Recombination in a Variety of Tissues in a Dose-Dependent Manner

The efficiency of Flp recombination at target *FRTZ* loci was assayed by Southern analysis. Genomic DNA isolated from doubly transgenic adult mice (target line *FRTZ-4999*; *FLP-4917*) was hybridized with a *lacZ* probe (probe 1 in Fig. 3A) to allow simultaneous detection of the target *FRTZ* transgene and the product of recombination. The new 4.4-kb DNA fragment resulting from the recombined target was present only in samples from doubly transgenic animals, and absent in DNA isolated from either target *FRTZ* or *FLP* littermates.

The amount of recombination product detected by Southern analysis was found to correlate directly with the amount of *FLP* mRNA detected in each tissue by Northern hybridization examined (e.g., liver, muscle, testes). Estimates of recombination efficiency were obtained from phosphorimage quantification of recombined (4.4-kb) to non-recombined (5.6-kb) bands. In muscle, approximately 30% of the transgenes were in the

recombined (4.4-kb) configuration. This represents an average of the actual recombination achieved in the various cell types isolated when dissecting muscle tissue (myofibrils, connective tissue fibroblasts, vascular endothelial cells, lymph node cells, blood cells). The value of 30% therefore represents a low estimate of the maximal recombination efficiency. This frequency is consistent with that observed in the EF cell culture assay derived from the same *FLP-4917* mouse line (45%); indeed, both cell populations showed similar amounts of *FLP* mRNA. Hybridizing with a probe specific to DNA between the *FRT* sites detected only the unrecombined fragment.

The Recombined Transgene Is Stably Transmitted Through the Germline

A prerequisite to using Flp to genetically manipulate cell lineages is that the recombination product be stable and heritable. Germline transmission of the recombined transgene was demonstrated by outcrossing a doubly transgenic (*FRTZ-5000; FLP-4917*) male and genotyping progeny by PCR. Both recombined and unrecombined transgenes were detected in this singly transgenic F_3 mouse indicating that recombination was incomplete; a subset of the 30 *FRTZ* transgenes in tandem array underwent recombination.

Conditional Expression of Flp Can Induce Regulated Rearrangement of Target Sequences in Differentiating EC Cells

Controlling expression of the *FLP* transgene is a way to restrict recombination, and therefore gene activation or inactivation, to a specific cell population (e.g., those cells expressing sufficient Flp activity to catalyze *FRT* site-specific recombination). Whether Flp-mediated recombination could be induced in a differentiating EC cell culture system

by using *Wnt-1* regulatory sequences (Echelard et al., 1994) to express *FLP* (see Fig. 3B for *Wnt1::FLP* transgene) was investigated. Retinoic acid (RA) can induce pluripotent P19 EC cells to differentiate into a mixed population of fibroblasts, astrocytes, and neural cells (Rudnicki and McBurney, 1987; Schuurin et al., 1989). In this manner, *Wnt-1* expression is likely induced specifically in neural derivatives, paralleling that seen in embryos where *Wnt-1* mRNA is detected in differentiating neuroectoderm (Wilkinson et al., 1987).

P19 cells were transiently transfected with target plasmid, target plus *phACTB::FLP*, or target plus *pWnt1::FLP*; 0.5 μ M RA or control diluent was added to the monolayer twenty four hours later. Following five days of RA treatment, β Gal activity was assessed by histochemical XGal staining. Neural induction was monitored by morphology (the presence of long cellular processes) and culture senescence, as well as by induction of endogenous *Wnt-1* mRNA.

β Gal activity was detected in target plus *pWnt1::FLP* cotransfections only following RA induced differentiation. Similarly, endogenous *Wnt-1* expression was absolutely dependent on RA. Low levels of *Wnt-1* transcripts were first detected by Northern hybridization after four days of RA treatment; no *Wnt-1* RNA was detected in untreated cells. As predicted by the nature of the *hACTB* regulatory sequences, β Gal-positive cells were observed in the target plus *phACTB::FLP* cotransfections independent of RA. The target plasmid alone showed no activity. In addition to demonstrating regulated rearrangement of target sequences, these results define a temporal relationship between *FLP* expression and completed recombination. β Gal activity, reflecting *Flp*-recombination, was observed in the target plus *pWnt1::FLP* cotransfection within 24 hours of first detecting *Wnt-1* transcripts, and by inference *Wnt1::FLP* mRNA.

Conclusions

The present example demonstrates that Flp can effectively recombine extrachromosomal target DNA in ES cells, EC cells and chromosomal target DNA in transgenic mice. Flp can direct site-specific and heritable DNA recombination in the mouse, and regulated (inducible) recombination in differentiating EC cells. These properties indicate that Flp can be used to make directed modifications of a transgenic non-human mammalian genome.

Using the Flp-FRT system, recombination of an extrachromosomal target can occur in ES cells with an efficiency similar to that previously observed in mouse embryonal carcinoma (F9) cells (O'Gorman et al., 1991) and in monkey (CV-1) and human (293) embryonic kidney cells (O'Gorman et al., 1991; Logie and Stewart, 1994). Because the efficiency of Flp recombination on an extrachromosomal substrate estimated here (30-78%) is comparable to that reported for Cre on a chromosomal substrate (40-80%; Gu et al., 1993), the Flp-FRT system can likely be exploited to similarly manipulate ES cell chromosomal DNA. Towards this end, a more elaborate two-step selection scheme was employed where Flp-mediated deletion of an integrated selectable marker gene (*PGK-neo*) was reported to occur in 90% of Flp-expressing ES cells (Fiering et al., 1995).

In the mouse, the present example shows Flp expression is necessary and sufficient for excisional recombination of *FRT* target sequences. Because recombination was detected at all three chromosomal sites assayed, it is likely that most chromosomal transgenes will be accessible to Flp function. The extent of recombination observed in a given tissue correlated directly with the overall amount of *FLP* mRNA detected in that tissue; it is important to note that this type of tissue analysis presents an average and

therefore may underestimate the maximal recombination achieved in a specific cell type. Nonetheless, these results define a dose-effect relationship which suggests that different degrees of recombination (frequent or rare) can be attained by varying the strength and specificity of the sequences used to express *FLP*. For some experiments, complete (quantitative) recombination may be needed. The results presented here suggest that one means to achieve this is to increase the level of *FLP* expression. Alternative strategies include identifying Flp variants with higher activity in mammalian cells, or to enhance the nuclear localization of Flp.

The finding that Flp can be generally expressed in the mouse without adverse effects suggests that Flp-recombination between random sequences in the mouse genome is rare. If high levels of illegitimate (non-*FRT*) recombination were occurring due to Flp expression, abnormalities would be expected in *FLP* founders or offspring. No adverse effects were detected. This result suggests that Flp can be used to mediate recombination in a variety of cell types.

Flp-mediated excisional recombination is sufficiently dose sensitive that recombination can be regulated in differentiating EC cells in culture. This was evident from examination of RA-treated P19 cells in which the *Wnt-1* promoter was used to express *FLP*. The temporal induction of *Wnt-1* transcripts following RA-induced differentiation indicates that recombination occurred relatively quickly: *FLP* expression, recombination of the target transgene to reconstitute a functional *lacZ* gene, and subsequent β Gal production occurred within twenty four hours. These results demonstrate that regulated rearrangement of a target sequence can be achieved.

The demonstration that Flp can excise DNA in mice and that the recombination product is heritable, suggests that Flp will be useful to study cell lineages. Considering this potential application, the initial test recombination substrate was designed to indicate and “remember” a recombination event by the irreversible gain of β Gal activity (dependent only on constitutive promoter activity). Mice transgenic for this target should have the capability of marking cell lineages following introduction of Flp by crossing. Towards this end, mice transgenic for *Wnt1::FLP* have been generated; by crossing to an “optimal” target mouse, cells originating from the dorsal aspect of the developing central nervous system are predicted to be marked. Although all three *FRTZ* target lines analyzed here were competent for recombination, none of the recombined target alleles were sufficiently active to allow cell marking by XGal stain. The lack of β Gal activity associated with the observed recombination most likely reflects a position effect on transgene transcription exerted by the genomic integration site since only one in four control *FRTZ-product* mouse lines expresses β Gal. Such sensitivity to chromosomal context is also supported by the variation in transcript profiles observed when using the same *hACTB* regulatory sequences to direct *FLP* expression (two of five lines showed general expression). Importantly, by screening additional *FRTZ* target loci, a chromosomal integration site has been identified that can support *lacZ* expression following Flp-recombination.

These examples demonstrate that Flp can serve as a tool to alter a mammalian genome *in vivo*. By employing Flp and another recombinase (e.g., Cre and site-specific recombinases cited in U.S. Pat. No. 5,434,066), it should be possible to engineer multiple recombination reactions (multiple gene activation or inactivation events) in a transgenic non-human mammal.

While the present invention has been described in connection with what is presently considered to be practical and preferred embodiments, it is understood that the present invention is not to be limited or restricted to the disclosed embodiments but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

Thus, it is to be understood that variations in the described invention will be obvious to those skilled in the art without departing from the novel aspects of the present invention and such variations are intended to come within the scope of the claims below. In particular, although the claimed invention is described in terms of the Flp recombinase, wild type Flp and the Flp-F70L mutant protein (SEQ ID NO:17), and the Flp-recognition sequence (e.g., FRT such as, for example, SEQ ID NOS:14 and 15), one skilled in the art would understand that functional equivalents of Flp recombinase and Flp-recognition sequences could be used in the context of the claimed invention and are intended to come within the scope of the claims below.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Susan DYMECKI
- (ii) TITLE OF INVENTION: Use of Flp Recombinase in Mice
- (iii) NUMBER OF SEQUENCES: 23
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Pillsbury Madison & Sutro, L.L.P.
 - (B) STREET: 1100 New York Avenue, N.W.
 - (C) CITY: Washington
 - (D) STATE: D.C.
 - (E) COUNTRY: USA
 - (F) ZIP: 20005-3918
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: Microsoft Word
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 79 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCGGTGAAGT TCCTATTCCG AAGTTCCTAT TCTCTAGAAA GTATAGGAAC

50

TTCCCTAGGA GATCTTCGAA GGCTCGAGC

79

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TAGCTACGTA GAAGTTCCTA TTCCGAAGTT CCTATTCTCT AGAAAGTATA 50

GGAAGTTCA 59

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 54 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTAGGGAAAGT TCCTATACTT TCTAGAGAAT AGGAACTTCG GAATAGGAAC 50

TTCA 100

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 84 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCGGTGAAGT TCCTATACTT TCTAGAGAAT AGGAACTTCG GAATAGGAAC 50

TTCTACGTAG CTAGCTCGAG CCTTCGAAGA TCTC 84

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTAAGGTACC GGTGAAGTTC CTA

23

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTCACCCACC GGTGAAGTTC CTA

23

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 211 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GGTACCGAGC TCAGCCACCA TGACTGCTCC AAAGAAGAAG CGTAAGGTAC	50
CGGTGAAGTT CCTATTCCGA AGTTCCTATT CTCTAGAAAG TATAGGAACT	100
TCACCGGTGG GTGAAGACCA GAAACAGCAC CTCGAACTGA GCCGCGATAT	150
TGCCCAGCGT TTCAACGCGC TGTATGGCGA GATCGATCCC GTCGTTTTAC	200
AACGTCGTGA C	211

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 64 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Thr	Ala	Pro	Lys	Lys	Lys	Arg	Lys	Val	Pro	Val	Lys	Phe	Leu
1				5					10					15
Phe	Arg	Ser	Ser	Tyr	Ser	Leu	Glu	Ser	Ile	Gly	Thr	Ser	Pro	Val
				20					25					30
Gly	Glu	Asp	Gln	Lys	Gln	His	Leu	Glu	Leu	Ser	Arg	Asp	Ile	Ala
				35					40					45
Gln	Arg	Phe	Asn	Ala	Leu	Tyr	Gly	Glu	Ile	Asp	Pro	Val	Val	Leu
				50					55					60
Gln	Arg	Arg	Asp											

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ala	Pro	Lys	Lys	Lys	Arg	Lys	Val
1				5			

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Lys Phe Leu Phe Arg Ser Ser Tyr Ser Leu Glu Ser Ile Gly Thr
1 5 10 15

Ser

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Pro Val Gly Glu Asp Gln Lys Gln His Leu Glu Leu Ser Arg Asp
1 5 10 15

Ile Ala Gln Arg Phe Asn Ala Leu Tyr Gly Glu Ile
20 25

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAAGTTCCTA TTC

13

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAAGTTCCTA TAC

13

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAAGTTCCTA TTCTCTAGAA AGTATAGGAA CTTC

34

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GAAGTTCCTA TTCCGAAGTT CCTATTCTCT AGAAAGTATA GGAAGTTC

48

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1272 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ATGCCACAAT TTGATATATT ATGTAAAACA CCACCTAAGG TGCTTGTTCTG TCAGTTTGTG 60
GAAAGGTTTG AAAGACCTTC AGGTGAGAAA ATAGCATTAT GTGCTGCTGA ACTAACCTAT 120
TTATGTTGGA TGATTACACA TAACGGAACA GCAATCAAGA GAGCCACATT CATGAGCTAT 180
AATACTATCA TAAGCAATTC GCTGAGTTTG GATATTGTCA ACAAGTCACT GCAGTTTAAA 240

TACAAGACGC AAAAAGCAAC AATTCTGGAA GCCTCATTAA AGAAATTGAT TCCTGCTTGG 300
GAATTTACAA TTATTCCTTA CTATGGACAA AAACATCAAT CTGATATCAC TGATATTGTA 360
AGTAGTTTGC AATTACAGTT CGAATCATCG GAAGAAGCAG ATAAGGGAAA TAGCCACAGT 420
AAAAAATGC TTAAAGCACT TCTAAGTGAG GGTGAAAGCA TCTGGGAGAT CACTGAGAAA 480
ATACTAAATT CGTTTGAGTA TACTTCGAGA TTTACAAAAA CAAAACTTT ATACCAATTC 540
CTCTTCCTAG CTACTTTCAT CAATTGTGGA AGATTCAGCG ATATTAAGAA CGTTGATCCG 600
AAATCATTTA AATTAGTCCA AAATAAGTAT CTGGGAGTAA TAATCCAGTG TTTAGTGACA 660
GAGACAAAGA CAAGCGTTAG TAGGCACATA TACTTCTTTA GCGCAAGGGG TAGGATCGAT 720
CCACTTGTAT ATTTGGATGA ATTTTGTAGG AATTCTGAAC CAGTCCTAAA ACGAGTAAAT 780
AGGACCGGCA ATTCTTCAAG CAACAAGCAG GAATACCAAT TATTAAGAAG TAACTTAGTC 840
AGATCGTACA ACAAAGCTTT GAAGAAAAAT GCGCCTTATT CAATCTTTGC TATAAAAAAT 900
GGCCCAAAAT CTCACATTGG AAGACATTTG ATGACCTCAT TTCTTTCAAT GAAGGGCCTA 960
ACGGAGTTGA CTAATGTTGT GGGAAATTGG AGCGATAAGC GTGCTTCTGC CGTGGCCAGG 1020
ACAACGTATA CTCATCAGAT AACAGCAATA CCTGATCACT ACTTCGCACT AGTTTCTCGG 1080
TACTATGCAT ATGATCCAAT ATCAAAGGAA ATGATAGCAT TGAAGGATGA GACTAATCCA 1140
ATTGAGGAGT GGCAGCATAT AGAACAGCTA AAGGGTAGTG CTGAAGGAAG CATACGATAC 1200
CCCGCATGGA ATGGGATAAT ATCACAGGAG GTACTAGACT ACCTTTCATC CTACATAAAT 1260
AGACGCATAT AA 1272

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 423 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met	Pro	Gln	Phe	Asp	Ile	Leu	Cys	Lys	Thr	Pro	Pro	Lys	Val	Leu
1				5					10					15
Val	Arg	Gln	Phe	Val	Glu	Arg	Phe	Glu	Arg	Pro	Ser	Gly	Glu	Lys
				20					25					30
Ile	Ala	Leu	Cys	Ala	Ala	Glu	Leu	Thr	Tyr	Leu	Cys	Trp	Met	Ile
				35					40					45
Thr	His	Asn	Gly	Thr	Ala	Ile	Lys	Arg	Ala	Thr	Phe	Met	Ser	Tyr
				50					55					60

Asn Thr Ile Ile	Ser Asn Ser Leu Ser	Leu Asp Ile Val Asn Lys
65	70	75
Ser Leu Gln Phe	Lys Tyr Lys Thr Gln	Lys Ala Thr Ile Leu Glu
80	85	90
Ala Ser Leu Lys	Lys Leu Ile Pro Ala	Trp Glu Phe Thr Ile Ile
95	100	105
Pro Tyr Tyr Gly	Gln Lys His Gln Ser	Asp Ile Thr Asp Ile Val
110	115	120
Ser Ser Leu Gln	Leu Gln Phe Glu Ser	Ser Glu Glu Ala Asp Lys
125	130	135
Gly Asn Ser His	Ser Lys Lys Met Leu	Lys Ala Leu Leu Ser Glu
140	145	150
Gly Glu Ser Ile	Trp Glu Ile Thr Glu	Lys Ile Leu Asn Ser Phe
155	160	165
Glu Tyr Thr Ser	Arg Phe Thr Lys Thr	Lys Thr Leu Tyr Gln Phe
170	175	180
Leu Phe Leu Ala	Thr Phe Ile Asn Cys	Gly Arg Phe Ser Asp Ile
185	190	195
Lys Asn Val Asp	Pro Lys Ser Phe Lys	Leu Val Gln Asn Lys Tyr
200	205	210
Leu Gly Val Ile	Ile Gln Cys Leu Val	Thr Glu Thr Lys Thr Ser
215	220	225
Val Ser Arg His	Ile Tyr Phe Phe Ser	Ala Arg Gly Arg Ile Asp
230	235	240
Pro Leu Val Tyr	Leu Asp Glu Phe Leu	Arg Asn Ser Glu Pro Val
245	250	255
Leu Lys Arg Val	Asn Arg Thr Gln Asn	Ser Ser Ser Asn Lys Gln
260	265	270
Glu Tyr Gln Leu	Leu Lys Asp Asn Leu	Val Arg Ser Tyr Asn Lys
275	280	285
Ala Leu Lys Lys	Asn Ala Pro Tyr Ser	Ile Phe Ala Ile Lys Asn
290	295	300
Gly Pro Lys Ser	His Ile Gly Arg His	Leu Met Thr Ser Phe Leu
305	310	315
Ser Met Lys Gly	Leu Thr Glu Leu Thr	Asn Val Val Gly Asn Trp
320	325	330
Ser Asp Lys Arg	Ala Ser Ala Val Ala	Arg Thr Thr Tyr Thr His
335	340	345
Gln Ile Thr Ala	Ile Pro Asp His Tyr	Phe Ale Leu Val Ser Arg
350	355	360
Tyr Tyr Ala Tyr	Asp Pro Ile Ser Lys	Glu Met Ile Ala Leu Lys
365	370	375

Asp Glu Thr Asn Pro Ile Glu Glu Trp Gln His Ile Glu Gln Leu
380 385 390

Lys Gly Ser Ala Glu Gly Ser Ile Arg Tyr Pro Ala Trp Asn Gly
395 400 405

Ile Ile Ser Gln Glu Val Leu Asp Tyr Leu Ser Ser Tyr Ile Asn
410 415 420

Arg Arg Ile

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1272 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATGCCACAAT TTGATATATT ATGTAAAACA CCACCTAAGG TGCTTGTTTCG TCAGTTTGTG 60

GAAAGGTTTG AAAGACCTTC AGGTGAGAAA ATAGCATTAT GTGCTGCTGA ACTAACCTAT 120

TTATGTTGGA TGATTACACA TAACGGAACA GCAATCAAGA GAGCCACATT CATGAGCTAT 180

AATACTATCA TAAGCAATTC GCTGAGTTTC GATATTGTCA ACAAGTCACT GCAGTTTAAA 240

TACAAGACGC AAAAAGCAAC AATTCTGGAA GCCTCATTAAGAAAATTGAT TCCTGCTTGG 300

GAATTTACAA TTATTCCTTA CTATGGACAA AAACATCAAT CTGATATCAC TGATATTGTA 360

AGTAGTTTGC AATTACAGTT CGAATCATCG GAAGAAGCAG ATAAGGGAAA TAGCCACAGT 420

AAAAAATGC TTAAAGCACT TCTAAGTGAG GGTGAAAGCA TCTGGGAGAT CACTGAGAAA 480

ATACTAAATT CGTTTGAGTA TACTTCGAGA TTTACAAAAA CAAAAAATTT ATACCAATTC 540

CTCTTCCTAG CTACTTTCAT CAATTGTGGA AGATTCAGCG ATATTAAGAA CGTTGATCCG 600

AAATCATTTA AATTAGTCCA AAATAAGTAT CTGGGAGTAA TAATCCAGTG TTTAGTGACA 660

GAGACAAAGA CAAGCGTTAG TAGGCACATA TACTTCTTTA GCGCAAGGGG TAGGATCGAT 720

CCACTTGTAT ATTTGGATGA ATTTTGTGAG AATTCTGAAC CAGTCCTAAA ACGAGTAAAT 780

AGGACCGGCA ATTCTTCAAG CAACAAGCAG GAATACCAAT TATTAAAAGA TAACTTAGTC 840

AGATCGTACA ACAAAGCTTT GAAGAAAAAT GCGCCTTATT CAATCTTTGC TATAAAAAAT 900

GGCCCCAAAT CTCACATTGG AAGACATTTG ATGACCTCAT TTCTTTCAAT GAAGGGCCTA 960

ACGGAGTTGA CTAATGTTGT GGGAAATTGG AGCGATAAGC GTGCTTCTGC CGTGGCCAGG 1020

ACAACGTATA CTCATCAGAT AACAGCAATA CCTGATCACT ACTTCGCACT AGTTTCTCGG 1080

TACTATGCAT ATGATCCAAT ATCAAAGGAA ATGATAGCAT TGAAGGATGA GACTAATCCA 1140
ATTGAGGAGT GGCAGCATAT AGAACAGCTA AAGGGTAGTG CTGAAGGAAG CATACGATAC 1200
CCCGCATGGA ATGGGATAAT ATCACAGGAG GTACTAGACT ACCTTTCATC CTACATAAAT 1260
AGACGCATAT AA 1272

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 423 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Met	Pro	Gln	Phe	Asp	Ile	Leu	Cys	Lys	Thr	Pro	Pro	Lys	Val	Leu	1	5	10	15
Val	Arg	Gln	Phe	Val	Glu	Arg	Phe	Glu	Arg	Pro	Ser	Gly	Glu	Lys	20	25	30	
Ile	Ala	Leu	Cys	Ala	Ala	Glu	Leu	Thr	Tyr	Leu	Cys	Trp	Met	Ile	35	40	45	
Thr	His	Asn	Gly	Thr	Ala	Ile	Lys	Arg	Ala	Thr	Phe	Met	Ser	Tyr	50	55	60	
Asn	Thr	Ile	Ile	Ser	Asn	Ser	Leu	Ser	Phe	Asp	Ile	Val	Asn	Lys	65	70	75	
Ser	Leu	Gln	Phe	Lys	Tyr	Lys	Thr	Gln	Lys	Ala	Thr	Ile	Leu	Glu	80	85	90	
Ala	Ser	Leu	Lys	Lys	Leu	Ile	Pro	Ala	Trp	Glu	Phe	Thr	Ile	Ile	95	100	105	
Pro	Tyr	Tyr	Gly	Gln	Lys	His	Gln	Ser	Asp	Ile	Thr	Asp	Ile	Val	110	115	120	
Ser	Ser	Leu	Gln	Leu	Gln	Phe	Glu	Ser	Ser	Glu	Glu	Ala	Asp	Lys	125	130	135	
Gly	Asn	Ser	His	Ser	Lys	Lys	Met	Leu	Lys	Ala	Leu	Leu	Ser	Glu	140	145	150	
Gly	Glu	Ser	Ile	Trp	Glu	Ile	Thr	Glu	Lys	Ile	Leu	Asn	Ser	Phe	155	160	165	
Glu	Tyr	Thr	Ser	Arg	Phe	Thr	Lys	Thr	Lys	Thr	Leu	Tyr	Gln	Phe	170	175	180	
Leu	Phe	Leu	Ala	Thr	Phe	Ile	Asn	Cys	Gly	Arg	Phe	Ser	Asp	Ile	185	190	195	

Lys	Asn	Val	Asp	Pro	Lys	Ser	Phe	Lys	Leu	Val	Gln	Asn	Lys	Tyr
				200					205					210
Leu	Gly	Val	Ile	Ile	Gln	Cys	Leu	Val	Thr	Glu	Thr	Lys	Thr	Ser
				215					220					225
Val	Ser	Arg	His	Ile	Tyr	Phe	Phe	Ser	Ala	Arg	Gly	Arg	Ile	Asp
				230					235					240
Pro	Leu	Val	Tyr	Leu	Asp	Glu	Phe	Leu	Arg	Asn	Ser	Glu	Pro	Val
				245					250					255
Leu	Lys	Arg	Val	Asn	Arg	Thr	Gln	Asn	Ser	Ser	Ser	Asn	Lys	Gln
				260					265					270
Glu	Tyr	Gln	Leu	Leu	Lys	Asp	Asn	Leu	Val	Arg	Ser	Tyr	Asn	Lys
				275					280					285
Ala	Leu	Lys	Lys	Asn	Ala	Pro	Tyr	Ser	Ile	Phe	Ala	Ile	Lys	Asn
				290					295					300
Gly	Pro	Lys	Ser	His	Ile	Gly	Arg	His	Leu	Met	Thr	Ser	Phe	Leu
				305					310					315
Ser	Met	Lys	Gly	Leu	Thr	Glu	Leu	Thr	Asn	Val	Val	Gly	Asn	Trp
				320					325					330
Ser	Asp	Lys	Arg	Ala	Ser	Ala	Val	Ala	Arg	Thr	Thr	Tyr	Thr	His
				335					340					345
Gln	Ile	Thr	Ala	Ile	Pro	Asp	His	Tyr	Phe	Ala	Leu	Val	Ser	Arg
				350					355					360
Tyr	Tyr	Ala	Tyr	Asp	Pro	Ile	Ser	Lys	Glu	Met	Ile	Ala	Leu	Lys
				365					370					375
Asp	Glu	Thr	Asn	Pro	Ile	Glu	Glu	Trp	Gln	His	Ile	Glu	Gln	Leu
				380					385					390
Lys	Gly	Ser	Ala	Glu	Gly	Ser	Ile	Arg	Tyr	Pro	Ala	Trp	Asn	Gly
				395					400					405
Ile	Ile	Ser	Gln	Glu	Val	Leu	Asp	Tyr	Leu	Ser	Ser	Tyr	Ile	Asn
				410					415					420

Arg Arg Ile

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GGTCCAAC TG CAGCCCAAGC TTCC

24

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GTGGATCGAT CCTACCCCTT GCG

23

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GACTGCTCCA AAGAAGAAGC GTAAGG

26

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GCTATTACGC CAGCTGGCGA AAGG

24

CLAIMS:

1. A transgenic mouse comprising a Flp transgene integrated in a genome of the transgenic mouse, wherein the Flp transgene is expressed in a cell of the transgenic mouse at a level of recombinase activity sufficient to catalyze recombination between Flp-recognition sequences of the cell.
2. The transgenic mouse according to Claim 1, wherein the genome further comprises a Flp-recognition sequence.
3. The transgenic mouse according to Claim 2, wherein the Flp-recognition sequence is SEQ ID NO:14 or SEQ ID NO:15.
4. The transgenic mouse according to Claim 2, wherein the transgenic mouse contains at least two diploid cells with different numbers of Flp-recognition sequences.
5. The transgenic mouse according to Claim 2, wherein the genome is hemizygous for the Flp-recognition sequence.
6. The transgenic mouse according to Claim 1, wherein the genome comprises at least two Flp-recognition sequences.

7. The transgenic mouse according to Claim 6, wherein the genome comprises at least two chromosomes, each chromosome comprising a Flp-recognition sequence.
8. The transgenic mouse according to Claim 1, wherein the genome further comprises two Flp-recognition sequences in direct repeat orientation.
9. The transgenic mouse according to Claim 1, wherein the genome further comprises two Flp-recognition sequences in inverted repeat orientation.
10. The transgenic mouse according to Claim 1, wherein the genome further comprises a Cre transgene.
11. The transgenic mouse according to Claim 1, wherein the genome further comprises a drug selectable marker transgene flanked by Flp-recognition sequences, wherein the drug selectable marker is excised in cells containing sufficient Flp recombinase activity.
12. The transgenic mouse according to Claim 1, wherein the genome further comprises another transgene flanked by Flp-recognition sequences.
13. The transgenic mouse according to Claim 12, wherein said another transgene is flanked by Flp-recognition sequences in direct repeat orientation.

14. The transgenic mouse according to Claim 12, wherein said another transgene is flanked by Flp-recognition sequences in inverted repeat orientation.

15. The transgenic mouse according to Claim 12, wherein said another transgene is selected from the group consisting of developmental gene, essential gene, cytokine gene, neurotransmitter gene, neurotransmitter receptor gene, oncogene, tumor suppressor gene, selectable marker, and histochemical marker.

16. The transgenic mouse according to Claim 15, wherein said another transgene is flanked by Flp-recognition sequences in direct repeat orientation.

17. The transgenic mouse according to Claim 15, wherein said another transgene is flanked by Flp-recognition sequences in inverted repeat orientation.

18. The transgenic mouse according to Claim 12, wherein expression of said additional transgene is activated in cells containing sufficient Flp recombinase activity.

19. The transgenic mouse according to Claim 12, wherein expression of said additional transgene is inactivated in cells containing sufficient Flp recombinase activity.

20. The transgenic mouse according to Claim 1, wherein Flp recombinase activity is regulated by a factor selected from the group consisting of chemical, developmental stage, temperature, and tissue type.

21. The transgenic mouse according to Claim 1, wherein the Flp transgene encodes amino acid sequence SEQ ID NO:17 or SEQ ID NO:19.
22. A transgenic mouse comprising a Flp transgene, wherein the Flp transgene is expressed in a cell of the transgenic mouse at a level of recombinase activity sufficient to catalyze recombination between Flp-recognition sequences of the cell.
23. A transgenic mouse comprising a genome which contains a Flp transgene and a Flp-recognition sequence.
24. A method of *in vivo* genetic engineering comprising:
- (a) providing a transgenic mouse comprising a genome which contains a Flp transgene and at least two Flp-recognition sequences,
 - (b) expressing the Flp transgene at a level of recombinase activity sufficient to catalyze site-specific recombination in a cell, and
 - (c) catalyzing recombination between the two Flp-recognition sequences of the cell.
25. The method according to claim 24, wherein site-specific recombination occurs in a germ line cell.
26. The method according to claim 25, further comprising:

(d) mating the transgenic mouse to produce an offspring comprising a recombined genome which does not contain the Flp transgene.

27. The method according to claim 24, wherein site-specific recombination occurs in a somatic cell.

28. The method according to Claim 24, wherein at least one of the Flp-recognition sequences is SEQ ID NO:14 or SEQ ID NO:15.

29. The method according to Claim 24, wherein the genome comprises at least two chromosomes and each chromosome contains a Flp-recognition sequence, whereby recombination between the two Flp-recognition sequences causes chromosomal translocation.

30. The method according to Claim 24, wherein the genome comprises a chromosome and the two Flp-recognition sequences are direct repeats flanking a target sequence on the chromosome, whereby recombination between the two Flp-recognition sequences causes excision of the target sequence.

31. The method according to Claim 30, wherein the target sequence is a drug selectable marker.

32. The method according to Claim 24, wherein the genome comprises a chromosome containing a first Flp-recognition sequence and a target sequence containing a second Flp-recognition sequence, whereby recombination between the two Flp-recognition sequences causes insertion of the target sequence into the chromosome.

33. The method according to Claim 24, wherein the genome comprises a chromosome containing a first Flp-recognition sequence and a plasmid containing a transgene and a second Flp-recognition sequence, whereby recombination between the two Flp-recognition sequences causes insertion of the transgene into the chromosome.

34. The method according to Claim 24, wherein the genome comprises a chromosome and the two Flp-recognition sequences are inverted repeats flanking a target sequence on the chromosome, whereby recombination between the two Flp-recognition sequences causes inversion of the target sequence.

35. The method according to Claim 34, wherein expression of the target sequence is increased by the inversion.

36. The method according to Claim 34, wherein expression of the target sequence is decreased by the inversion.

37. The method according to Claim 24, wherein recombination causes activation of an oncogene or inactivation of a tumor suppressor gene in the cell, thereby transforming the cell and establishing a probability of developing cancer in the transgenic mouse.

38. The method according to Claim 37, further comprising:

- (d) administering a candidate agent to the transgenic mouse; and
- (e) identifying the candidate agent as a cancer promoter if the probability of developing cancer increases or a cancer inhibitor if the probability of developing cancer decreases.

39. The method according to claim 37, wherein the oncogene is selected from the group consisting of ABL1, BCL1, BCL2, BCL6, CBFA2, CBL, CSF1R, ERBA, ERBB, EBRB2, ETS1, ETV6, FGR, FOS, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TAL1, TCL3, and YES.

40. The method according to claim 37, wherein the tumor suppressor gene is selected from the group consisting of APC, BRCA1, BRCA2, DCC, MADH4, MCC, NF1, NF2, RB1, WT1, and TP53.

41. The method according to claim 24, wherein Flp-mediated recombination activates ectopic expression of a developmental gene.

42. The method according to claim 24, wherein Flp-mediated recombination inactivates post-embryonic expression of a developmental gene required for embryonic development of the transgenic mouse.
43. The method according to claim 24, wherein Flp-mediated recombination identifies a cell lineage in the transgenic mouse.
44. The transgenic mouse according to Claim 24, wherein the Flp transgene encodes amino acid sequence SEQ ID NO:17 or SEQ ID NO:19.
45. A system for genetic manipulation, comprising:
- (a) the transgenic mouse according to Claim 22, and
 - (b) a purified nucleic acid comprising a Flp-recognition sequence.
46. The system according to Claim 45, wherein the Flp-recognition sequence is SEQ ID NO:14 or SEQ ID NO:15.
47. The system of claim 45, wherein the purified nucleic acid further comprises a sequence selected from the group consisting of developmental gene, essential gene, cytokine gene, neurotransmitter gene, neurotransmitter receptor gene, oncogene, tumor suppressor gene, selectable marker, and histochemical marker.
48. The system of claim 45, further comprising:

(c) means for producing a transgenic mouse comprising a genome which contains the Flp-recognition sequence.


49. The system of claim 45, wherein the Flp transgene encodes amino acid sequence SEQ ID NO:17 or SEQ ID NO:19.

Patent Application No. 2016/0100000


ABSTRACT OF THE DISCLOSURE

A method is disclosed for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites (e.g., a DNA sequence containing an *FRT* site). The invention in particular discloses the use of site-specific recombinases such as Flp recombinase to accomplish *in vivo* recombination at engineered chromosomal FRT sites, thereby forming the basis of a genetic system to mark cell populations and lineages, as well as to activate, delete, mutate, or rearrange genes *in vivo*. DNA constructs are provided for the creation of Flp and FRT transfected eukaryotic cells or transgenic non-human mammals.


A pFLP




B placZ




C pFRT₂




pFRT₂lacZ



pFRT₂neo.lacZ



pFRT.lacZ



11-9-1



[illegible]

Fig. 3


A

pFRTZ




B

phACTB::FLP



pWnt1::FLP



C

